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ABSTRACT 
THE RELATIONSHIP BETWEEN ORAL CONTRACEPTIVES AND INTRA­
EPITHELIAL NEOPLAS IA OF THE UTERINE CERVIX 
Barbara Jeann e t t e  Fox , R . N .  
Medical C o l l ege o f  Virginia-Virginia Commonweal th 
University , 1984 
Maj or Direc tor : E.  Chris ta S t ern , R . N . , Dr . P . H .  
The purpose o f  this s tudy was t o  determine the r e lation-
ship be tween specific oral contraceptive use and cervical 
in t raepi the lial neoplasia ( CI N ) , and to determine if 
duration of u s e  and con tent of oral con tracep tives were 
r e lated to CIN . The hypo thes e s  t e s ted in this s t udy wer e : 
( 1 )  norges tr e l -con taining oral con tracep tives are a�socia ted 
with mor e  s evere l evel� :o f  CIN , and ( 2 )  longer duration of 
oral con traceptive use  is as s ociated with more severe CIN . 
Data was col lected f rom 52 c linical records of  c lien t s  
who attended a co lpos copy c linic during a f our month period . 
C lien t s  inc luded in the s tudy were u tilizing one of  five 
s pecific oral con traceptives for a minimum of six con tinuous 
months . During their initial c linic visit , a l l  clien t s  were 
in terviewed by the co lposcopy c linic nur s e  who recorded 
information concerning duration and type of oral con tra-
ceptive use on par t one of  an inves tigator-designed data 
c o l l ec tion form . From the data c o l l ec tion forms comple t ed 
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by the nurse , the inves t igator de termined clinical record 
eiigibili ty for inclusion in the s tudy . The invest igator 
u t ilized part two of  the data collec t ion form to record age , 
race and colposcopic diagnosis from the clien t  clin ical 
record . 
The maj o r i ty o f  s tudy clien ts were black and younger 
than 26 years of age .  The dura t ion of oral con tracept ive use 
r anged f rom six to 96 mon ths . Or thoNovum 1/50 ( ON 1/50 ) was 
the most f requen tly used , and LoOvral was the least 
frequen tly used , oral con tracept ive . Mild/moderate dysplasia 
was the most frequen t CIN diagnosis and carcinoma in s i tu 
( CI S )  was the· least f r equen t .  Condyloma was the second most 
f requen t CIN diagnosis . 
Or thoNovum . .  1 /35 ( ON 1/35 ) users had the highest 
frequency of  mild dysplasia , and the highest Est ima te of  
Relat ive Risk ( ERR ) of  mild/modera te dysplasi a .  Users of  
� 35 meg . estrogen oral con tracept ives had a higher percen tage 
and ERR of mild/modera te dysplasia than users of 50 meg . 
estrogen oral contracep t ives . ON 1 /35 and Loestrin users 
had no severe dysplasia/CIS diagnoses . 
ON 1/50 and Ovral users ( 50 meg . estrogen oral con tra­
cept ives ) had a higher percen t age and ERR of  severe 
dysplasia/CIS and condyloma than users of  � 35 meg . estrogen 
oral con tracept ives . Loestrin users had the highes t overall 
percen tage and ERR o f  condyloma , and LoOvral users had the 
19west overall percen tage and ERR of condyloma . O f  those 
i x  
clien ts wi th 1 2  or more mon ths of  oral con tracep t ive use , 
the 50 meg . estrogen oral con tracept ive users had the 
highest percen tage of condyloma . Of the s tudy clien ts w i th 
1 2  mon ths or less oral con tracept ive use , the 50 meg . 
estrogen oral con tracept ive users had the lowest percen tage 
of condyloma . For all dura t i ons of  oral con tracept ive use , 
50 meg . estrogen users had the highest percen tage o f  sever e  
dysplasia/CIS . Users of  oral con tracept ives for 1 2  mon ths 
or less had a higher percen tage and ERR o f  severe 
dysplasia/CIS and condyloma than users of  oral con tracept ives 
for more than 1 2.mon ths . 
Users of  norges trel-containing oral con tracept ives had 
a higher percen tage and ERR o f  severe dysplasia/CIS and a 
lower percen tage of  condyloma and mild/moderate dysplasia 
than o ther oral con tracept ive users in the s tudy . 
F isher ' s  exact one - tail t es t  and Analysis of  Variance 
( ANOVA) showed a s ta t is t ically sign i f ican t d i f f erence in 
the inc idence of dysplasia be tween i 35 meg . estrogen and 
50 meg . estrogen oral contracept ive users . Fisher ' s  exac t 
one- tail t es t  also showed s t a t ist ically sign i f ican t 
d i f f erences in the inc idence of  dysplasia be tween ON 1/35 
and Ovral users . D i f f erences in the inc idence of  condyloma 
be tween norges trel-contain ing oral con tracept ives and o ther 
oral con tracept ive users wer e  n o t  statistically signi f ican t 
w i th Fisher ' s  exac t one- tail t�s t . 
X 
The invest igator concluded that there were 
d i f f erences be tween specif ic oral con tracept ives and the 
associa t ed inc idence of  CIN . The investigator also 
concluded tha t these d i f ferences were n o t  assoc ia ted w i th 
duration o f  oral con tracept ive use . 
x i  
CHAPTER ONE 
Introduction 
Contraception is a conscious ef fort to prevent the 
probabil ity of pregnancy ( Stedman , 1 9 7 6 ) .  To promote con­
trol of human ferti l ity , new advances in reproductive 
knowledge in the 1950's led to the deve lopment of oral 
contraceptives composed of hormones and their analog s . 
Oral contraceptives are the most widely u s ed drugs 
r equir ing a prescr iption . It i s  estimated that eight 
m i l l ion women in the Un ited States and 150  m i l l ion women 
wor ldwide u s e  the "pi l l" (Wrenn , 1 9 7 9 ) .  As a hormonal  prep­
aration , the ' '�ill"  inhibits ovu lation . Que stions con ­
c erning the safety and poss ible s ide e f f ects o f  ongo ing 
hormonal therapy have resulted in cons id�rable res earch , 
however , many questions r emain unan swered . 
Potential ly s er i ous s ide e f f ects assoc iated with oral 
contraceptives inc lude hypertens ion , thromboembo l itic 
d i s ea s e , cerebra l  vascular acc idents and endometr ial 
hyperplasia . Research has shown that oral contraceptive 
agents may have direct.effects on the gen ital tract by 
a ltering the status of the endometr ium and the cervical 
mucus ( Da l l enbach-He l lweg , 1 9 8 1 ) .  Cons iderable concern 
exists regarding the association of carcinomas of the 
uterus , cervix and vagina and the u s e  of oral contraceptives . 
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Among the s e  concerns is  the a s s oc iation between 
intraepithe l i a l  neoplasia of the uterine cervix ( CIN ) and 
oral contraceptive u�e . Many studies invo lving the 
a s s oc iation between cancer of the cervix and oral contra­
ceptives have been inconc lus ive ( Robbins and Co tran, 1 9 7 9 ) .  
A lthough i t  i s  s t i l l  uncertain whe ther o r a l  contracept ive 
use s ignif icantly increas es  the incidence of cervical 
cancer, r e s earch has shown tha t oral contracept ive use i s  
related t o  endome trial  and cervical tis sue changes . The 
po s s ible as sociat ion between oral contracept ive use and 
an increas ed risk.o f  C IN ha s been the subj ect of mor e  than 
1 2  maj or epidemiologic s tudi e s  ( Swan and Peti tti, 1 9 8 2) . 
The r esults o f  the s e  s tudies  are contradictory . Mos t  o f  
the studies conducted have been rela ted to the association 
between cervical cancer and factors such as  dysplas ia, age 
of menarche, number o f  sexua l par tners, age of f irst coitus, 
r ace, economic s tatus, and environmen tal  inf luences 
( Me i s els,  et al . ,  1 9 7 7; Stern, 1 9 7 1; Mi l ler, 1 9 7 3; Rotkin, 
1 9 8 1 ) .  
A number o f  recent studies have been concerned with 
the r elationship between C IN and condy loma . Condy loma 
acuminatum is caused by the Human Pap i l loma Virus and may 
mimic, precede or coexist wi th C IN. ( Ko s s, 1 9 8 3) . Mal ignan t 
tran s formation of these gen i t a l  warts has been documented 
( Me i s e l s  and Mor in, 1 9 8 1 ) .  Re search concerning CIN and 
condyloma has not investigated oral contraceptive use 
assoc iated with condyloma . 
Many studi e s  have focus ed on users vs . nonusers of 
oral contraceptives . Few studies  have been conducted on 
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the effects o f  the individual drugs on the user . A number 
of studies have researched the effects of spec i f ic combi ­
nations of estrogen and progesterone . Reactions reported 
with thes e  oral contraceptives have included breakthrough 
bleeding , changes in menstrual flow , spotting , changes in 
the cervical transf ormation z one , and viscos ity of cervical 
mucous s ecretion ( Dickey , 1 9 7 9 ) . A con s i stent outcome of 
thes e  studies  has been the need for further r e search related 
to as sociated e f f ects of oral contraceptives . 
The mo st s ignif icant way in which oral contraceptives 
may af fect cervical cancer is by an alteration of the 
hormonal balance which affects the immune response and 
metaboli sm ( Beral , 1 9 80 ) . Thi s  immune respons e  effect 
may interact with ind ividual hormonal and immune respon s e s . 
Rather than being a direct carcinogenic agent , oral contra­
c eptives may potentiate the susceptibility o f  the ind ividual 
to carcinogen ic influences . 
Research has shown that the r i s k  of cancer i s  related 
to the duration of e xposure to ·a carc inogen . Several 
studies have reported a r elation ship between the length 
and the potency of oral contraceptive use and the 
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deve lopmen t of  cervical cancer ( Ory , e t  a l . ,  1 9 7 7; 
Per i t z , e t  al . ,  1 9 7 7; Melamed and Flehinger , 1 9 7 3 ) . I t  
has been sugg e s t ed tha t the longer the durat ion of  u s e  and 
the higher the po tency of the oral contracept ive , the greater 
i s  the r i s k  for cervical cancer . 
B ecau s e  of  the r i s k  of  cervical cancer which may be 
a s s ocia ted w i th CIN and oral con tracept ive use , heal th care 
provider s prescribing thes e  prepara t i ons need to be aware 
of the po t en t i a l  hea l th r isks tha t can be avo ided by be ing 
a t ten t ive to the dura tion of use  and s trength of the oral 
c�n tracept ive prescr ibed for c l i en t s . This  s tudy wi l l  provide 
addi t ional informa t i on concerning the relationship be tween 
s peci f ic oral con tracept ives , durat ion of  use , and 
in traepi the l ial  neoplasia  of the uter ine cervix ( CIN ) . 
Problem Sta t ement 
The purpose o f  this s tudy was to determine the relat ion­
ship be tween spec i f i c  oral contracept ives and CIN , and to 
determine i f  dura t ion o f  u s e  and con t en t  of  the oral 
con tracept ive were r e lated t o  CIN . 
Hypo theses  
The hypo theses  �o  be  t e s t ed in this s tudy were : 
1 .  Norges trel-containing oral con tracept ive u s e  is  
a s s oc iat ed w i th more s evere leve l s  o f  CIN . 
2 .  Longer dura t ion o f  oral con tracept ive use i s  
as soc iated with more s evere leve l s  o f  CIN . 
Definition of Terms 
Speci f ic oral contraceptives inc luded in this  study 
were f ive drug preparations with estrogen and progestogen 
content ( Appendix A) . Thes e  f ive drug preparations 
repres ent two do sage strengths of estrogen and three 
progestogen s . 
Cervical Intraepithe lial  Neoplas i a  (CIN) is defined 
in this  study as  mild ,  moderate, and s evere dy splas ia , 
carc inoma in s itu , , and f lat condy loma acuminatum as  noted 
on the colpo scopic examination reports in 52 c l i ent 
medical records from a colposcopy c l inic in a large 
un ivers ity teaching hospital located in a southeastern 
state . 
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Duration of oral contraceptive use i s  defined as  the 
l ength of time the c l ient reported having taken the spec i f ic 
oral contraceptive which was being taken at the time of 
the CIN diagnos i s . A l l  c l i ents inc luded in the study had 
been taking the spec i f ic ora l contraceptive continuous ly 
f or a min imum o f  s i x  months . 
Assumptions 
1 .  All reports and inf ormation conta ined in the 
c l ient's record were accurately recorded . 
2 .  The f ive spec i f ic ora l contraceptive s studi ed 
6 
r epres ented the most common ly prescr ibed oral contraceptives .  
Limitations 
1 .  Because the study did not inc lude variables , such 
as  social and medical hi story and certain demographic 
variables , other factors that may have inf luenced the 
study results were not contr o l led . 
2 .  Becau s e  of geographic location and the l imited 
popu lation s ample , the study results cannot be genera li z ed .  
3 .  Some c l i ents may have beeti tis ing another oral 
contraceptive prior to the one reported in the study which 
could have influenced study results . 
D e l imitations 
1 .  A conveni ence samp l e  o f  diagnostic reports from 
52 c l ient medical records were uti l i z ed in this  study . 
2 .  On ly thos e  medical records o f  c l ients which met 
defined criter ia for spec i f ic oral contraceptive s were 
included in the study . 
3 .  Only thos e  c l inical records of c l i ents s een in 
the co lpo scopy c l inic s ite between October , 1 9 8 3  and 
March 1984  were included in the study . 
Conceptual Framework 
The conceptual framework for thi s  study inc ludes 
epidemiological concepts for the inve stigation of disease 
and Chr i sman and Fowler's System s - in - Change mode l ( 1 9 80).  
B o th nurs ing and epidemio logy are concerned w i th demo­
graphic, bio logic , socia l ,  psycho logical and cul tural 
charac ter i s tics o f  c l ien t s  and how these  rna� inf luence 
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the deve lopmen t o f  d i s ea s e  ( L i l ien f e ld and Lil ienfeld , 
1 9 8 0 ) . Chr isman and Fowler's model  ( 1 9 8 0 )  was s e lected 
because  i t  provides an organ i z ed approach to the asses smen t 
o f  change .  Epidemio logical concep t s  enable a s y s t ematic 
approach to the s tudy o f  a charac t er i s t ic ,  such as oral 
con traceptives , and d i sease . Thi s  s tudy of the relationship 
be tween spec i f ic oral con tracept ives and GIN u t i l i z e s  
epidemiological concepts  for the inve s t igat ion of d i s eas e .  
Epidemiological Concep t s  
Ideas of epidemio logy da t e  back to Hippocrates who 
emphas i z ed the importance of looking a t  environmen tal  
inf luences on d i s ease (Li lienfeld and L i l ienfeld , 1 9 80 ) . 
Epidemiology f ocuses on the pa t terns of disease  tha t occur 
in human populat ions and the bio logica l , chemica l ,  phy s ical 
and social factors tha t may inf luence these pa t t erns 
( L i l ienfeld and L i l i enfeld , 1 9 8 0 ) . An epidemio logical 
approach is  useful  for this s tudy because it enables  a 
s y s t ematic me thod to de termine a s ta t i s t ical  associat ion 
o f  a charac t er i s t ic ( spec i f i c  oral contracept ive) and 
d i s ease ( GIN). I t  a l s o  enables biological inferences from 
pat terns of s ta t i s t ical  as sociat ions , and i t  can provide 
a bas i s  for preven t a t ive hea l th care prac tices of pr imary 
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health care providers . 
The maj or concepts o f  epidemio logy inc lude agent, ho st, 
environment, time, place, person and spectrum of disease .  
Patterns o f  disease depend on the interaction o f  agent, 
host and environment which may be aff ected by time and place . 
Host and person may be cons idered synonymous . The host 
is the susceptible pers on . Characteri stics o f  the host 
inc lude demographic, biological, socioeconomic, pers onal 
and genetic variables ( L i l ienfeld and L i l ienf e ld, 1 9 80 ) . 
The ag;ent can be def ined as the " in f ectious" material or 
a precipitating event ( Li l i enfeld and Lil i enfeld, 1 9 80 ) , 
s uch as a "carcinogen ic" agent . It i s  pos s ible that both 
an in itiating agent and a promoting agent may be invo lved 
in the deve lopment of diseas e .  
The environment and place are inclus ive of each other . 
A s s oc iations with different leve l s  of disease have o ften 
been found in different geographic location s . The 
epidemiolog i st study ing inf ectious disease is  concerned 
with the spec i f i c  place where contact is made . This  know­
l edge is crucial in the study of epidemic s .  In the study 
of any disease entity, analy s i s  of disease di stribution 
can identify if some viral, environmental or cu ltural 
factor may be pre sent in more than one place or more 
prevalent in one popu lation than another . For examp le, 
the Epstein-Barr virus has been ,p inpointed as a likely 
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eti o l ogical agent in a number o f  di sease conditions 
inc luding tumors  that have spec i f ic geographic distr ibution 
( L i l i enfeld and Lil ienfeld,  1980) .  Environmental factors  
inc lude cu ltural factors , such as r e l igion , socioeconomic 
m i l ieu , and exposure to chemicals , occupational and personal 
l i festy l e  str e s s or s . Environmenta l factors could also  
include the person ' s  internal immuno logical and phy s i o logical 
condition•: 
T ime indicates the incubation per iod from the time 
of contact with the agent to the onset of i l ln e s s  or the 
manifestation of diseas e . The length and extent of exposure 
are important e l ements of the time concept in the deve lop­
ment of di s eas e . In order to demonstrate a cause in an 
epidemio l ogical study , a time s equence must be shown . 
Epidemio log ical investigations have shown that there is  
o ften a long latency period between causal exposure and 
c l in ical di sease ( Hutchison , 1 9 7 5) .  
The spectrum of disease refers to the sequence of 
events occurr ing in a human organ ism f rom the time o f  
contact with the etiological agent t o  death as soc iated with 
the di sease (Li l ienfeld and Li lienfeld ,  1980) .  This  may 
also  be cons idered the gradient of inf ection . Both sub­
c l in ical and c l inical stages  are inc luded in the diseas e 
spectrum even though on ly the c l inical stage may be noted . 
Whether a per son wi l l  go through the full  spectrum of 
d i s ease i s  dependent upon the ho st/per son ' s  immunolog ical 
status.and the preventative measures initiated by the 
health·eare provider , such as  screening , procedures , and 
treatments to inhibit further development of the disease . 
In  studying the prevalence and assoc iated patterns 
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o f  disea s e , epidemi ology attempts t o  integrate and investi­
gate the interactions o f  agent , host , environment , time , 
place ,  per s on and the spectrum of disease . Incorporation 
of thes e  f actors in health care practice enables the health 
care provider to a s s e s s  and evaluate phy s ical , psychological , 
and s ocioeconomic cli ent data . Thi s  data g ives the health 
care provider a better under standing of the poss ible 
e xplanations for thi s  information , and it enables inter­
vention in the progre s s ion and extens ion of disease in the 
client . 
The Systems - in-Change Model 
The System s - in - Change model was developed by Chr i sman 
and Fowler ( 1 980) for utili z ation in the ir nurs ing practice . 
They developed the model in an attempt to incorporate both 
systems and developmental theor ies  o f  stres s  and adaptation 
into their nurs ing practice . The model is comprehens ive 
and flexible and it i s  applicable to clin ical practice . 
Riehl and Roy ( 1 9 80) clas s i f ied the Systems - in - Change model 
as a developmental model for nurs ing practice . 
Chri sman and Fowler ( 1 980) include the following 
concepts in the ir Sy s tems - in- Change model for nurs ing 
prac t ic e :  ( 1) pro f e s s ional nurs ing's func t ions and 
activities  are direc ted by a therapeu tic purpos e ,  and ( 2) 
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the nur s e  suppor t s  and promo tes  hea l th and the qua l i ty of 
l i f e . The Sys t ems- in- Change model i s  bas ed on the f o l lowing 
as s umpt ion s : ( 1 ) man i s  viewed as  three dynamic sys t ems 
interact ing with each o ther and the environment along a 
developmen t a l  con t inuum , ( 2) the s ta tus o f  each sys tem and 
i t s  interac t ions inf luences hea l th ,  ( 3) the individual  move s 
f rom one deve lopmen t a l  s tage to ano ther w i th informa t ion 
and ef fec t s  of the· pas t being s tored for incorpora t ion into 
the pres en t and for u t i l i za t i on in the fu ture , and ( 4) change 
is inheren t in l i f e  and growth . 
The s tructure o f  the Sy s tems - in - Change model provides 
an organ i z ed way to a s s e s s  in t erdependen t fac t ors , such 
as physical developmen t ,  phy s i o logical sys tems , hea l th 
and s ocioeconomic mi lieu , in a c l i en t /pa t i en t s i tua t ion . 
The Sys tems - in - Change mode l emphas i z e s  s tructure compo sed 
o f  biologica l ,  social and per sonal  s y s tems and i t  s tates  
that the s e  are in a con t inua l proce s s  of change .  The model 
also emphas i z es the ac t ive proces s of change in individua l 
developmen t throughou t  l i f e . The process  iden t i f ies  the 
changes tha t inf luence growth , and the equ i l ibrium of each 
s y s t em invo lves tho s e  changes wi thin sys t ems , be tween 
s y s t ems , and changes  tha t occur along a deve lopmen tal  
continuum . The two bas ic components of the Systems-in­
Change mode l are the structure ( sy stems ) and the proces s  
( change ) .  
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The structure ( systems ) perceives man a s  a bio logical , 
s oc i a l, and personal sy stem that interacts and i s  open to 
the environment and to each system ( Chrisman and Fowler , 
1 9 8 0) .  Each of thes e  sy stems has its own internal organi­
zation and they are interdependent . They interact with 
each other as  an " integrated who le" and there i s  feedback 
among the s ystems and with the environment . Changes that 
occur ins ide or outs ide of the sy stems may produce stress  
which can di sturb the equ i l ibr ium o f  the systems . Assess­
ment o f  the sy stems inc ludes the state of equ i l ibr ium and 
the existence or absence of compen satory/regu latory 
mechanisms that help the individual sy stem achieve , r estore 
or maintain optimal function . Although the sy stem may be 
studied in the pres ent , the role  of the past and the future 
potential are incorporated into the as ses sment . 
The proce s s  ( change )  refers  to the stages of human 
development which range from the prenatal per iod through 
maturation and death . The c l i ent's present status 
a lway s con s i sts of a past as we l l  as a potential future .  
The c lient ' :s development inc ludes change which is  
inf luenced by  his  environment and genetics .  Thi s  change 
a f f ects a l l  sy stems . In a l l  stages of l i f e , deve lopment 
is an active proces s that invo lve s change . 
I n. a s s e s sment o f  developmen tal  change, a compar i s on 
i s  made of the fac tors observed, which indicate the 
developmen tal  s tage of the c l ien t's biological, social  and 
personal sys tems, w i th the s tages e xpect ed by the c l i en t's 
chronological age and sociocul tural mil ieu ( Chri sman and 
Fowler, 1 9 8 0) .  The general developmen tal  asses smen t tha t 
i s  es tabli shed by ga ther ing this inf orma t ion inf luences 
evaluat ion o f  the individual s y s t ems and guides the 
prac t i tioner in therapeu t ic goal s e t t ing and interven t ion . 
The prac t i t ioner can iden t i f y  the spec i f ic developmental 
problem and i f  a s ignif ican t di screpancy exi s ts be tween 
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the observed and the expec ted da ta, the prac t i t ioner can 
use spec i f i c  t o o l s  to fur ther a s s e s s  and focus on the 
problem. Changes of the sys tems are not  only deve lopmen t al, 
they are a l s o  con t inua l ly occurr ing in respon s e  to input 
proc es s ing f rom the ever chang ing internal and ex ternal 
environmen t ( Chri sman and Fowler, 1 980).  
Chr isman and Fowler's mode l a t temp t s  to enable the 
nur s e  to examine the many var iables, such as l i f e s tyle, 
occupat iona� s tress,  gen e t ics,  pas t  his tory, medicat ion 
u s e, and immune s y s t em which may af fect  the c l ien t at any 
one point in t ime . Becaus e  the model is open and f lexible, 
i t  perm i t s  incorpora t i on of a var iety  of concept s  and 
theor ies . The prac t i t ioner can then u t i l i z e  appropr iate 
epidemiological concept s  and empha$ i z e  aspec t s  of the mode l 
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that apply to the spec i f ic client s ituation . 
Chri sman and Fowler ( 1 980) identify the impl ications 
of their mode l for different leve l s  of nurs ing pers onnel  
and its  uti l i zation in the nurs ing proces s .  Their mode l 
pres ents a very spec i f ic asses sment tool that the prac ­
t�tion�r can uti l i z e  with the individual c l ient . The model 
also provides guide lines for establishment of diagno s i s , 
goal s ,  intervention and eva luation . The model can be 
applied to a variety of s ettings within the hospita l and 
in public hea lth by the nurse practitioner . The nurse prac­
titioner is concerned with the interaction of the sy stems 
with the environment , the c l ient ' s  deve lopmental stage , 
and the c l i ent's past , pres ent and future . 
The nurse practitioner ' s  a s s e s sment inc ludes an eva l­
uation of the current functioning of each c l i ent sy stem 
( bio logica l , social and personal) , the s igns and symptoms 
of dys functional changes within each system , and the environ­
menta l variables  that inf luence each system . The nurs ing 
diagnosis  is then based on the actual or potential dys function 
of one or more of the s ystems . Goa l s  for intervention and 
evaluation are deve loped from the diagno s i s . 
Chri sman and Fowler ' s  mode l is  particularly useful 
in thi s  study o f  the re lationship between ora l contra­
c eptives and GIN . The mode l addres s e s  the importance o f  
change which is  inherent i n  l i f e  and growth . Change may 
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occur within a normal cycle  and it may be aff ected by man's 
bio logy and environment . Norma l tis sue changes occur 
cycl ica l ly within a woman ' s  menstrual cycle . The etio logy 
o f  abnorma l cyto logy and cervica l tis sue change is sti l l  
uncertain; i t  may be due t o  a combination of factors that 
e x i st within the dynamic interaction of man ' s bio logy and 
the environment . Among thes e  f actor s  are oral contra­
ceptives, the ir a s s ociated hormona l inf luences, duration 
of exposure to contraceptives, and s ociodemographic factor s  
o f  the client . 
Uti l i z ing the Systems- in-Change mode l, the. nur se  prac­
titioner a s s e s s e s  past and pres ent bio logical, social, and 
per sonal sy stems of the cl i ent along with the state o f  
equ i l ibr ium of the sy stems . She then identi f ies  both the 
e xpected po int along the deve lopmenta l continuum and the 
actual observed po int o f  development . Identificati on of 
a deviation f rom the expected and observed po int of deve lop­
ment, combined with inf ormatiom f rom the data base, enables 
the establishment o f  a diagno s i s . Intervention could con s ist 
o f  counsel ing, appropr iate referral, education and/or adj ust­
ment of the client's medication . The nur s ing goal is  to 
enable the c li ent to r eturn to an equ i l ibr ium o f  sy stems . 
F o l low-up evaluation would determine i f  this  goal had been 
met . A continued d i s equi l ibrium would indicate a reas s e s s­
ment for more appropriate nur s ing intervention to alter 
the exis t ence of the d i s ease or the factors affec t ing the 
d i s ea s e  process; 
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Observa t ion by the prac t i t ioner o f  CIN and oral con tra­
cept ive ( agen t) use is cons idered w i th the interac t ion of 
all s y s tems inc luding the pas t ,  pre s en t  and future medical 
h i s t ory o f  the c l ien t . The nurse prac t i t ioner mus t  a l s o  
observe and cons ider the epidemiological proce s s  tha t ex i s t s  
w i th hos t ,  environmen t ,  and agen t in terac t ion i n  the develop­
men t of d i s eas e .  The prac t i t ioner a s s e s s e s  the interac t ion 
of the c l ien t/hos t's biological and immuno logical, personal 
and soc ia1!.s y s t ems ( environmen t) by u t i l i z ing the 
Sys t ems-in-Change model and notes  tha t the expec t ed normal  
cyto logical smear is  d i f f eren t from the obs erved changes 
in  cervical t i s sue . W i th an unders tanding of the interac t ion 
of the c l i en t ' s  s y s t ems , and the epidemio logical proce s s  
o f  CIN , t h e  prac t i t ioner may b e  able to a s s es s the c l ien t ' s  
risk for deve loping cervical cancer . 
The nur s e  prac t i t ioner can s e t  goa l s  for the promot ion 
o f  opt ima l heal th by u t i l i z ing the Sy s tems - in - Change mode l .  
She may recommend a d i f f erent oral con tracept ive wi th l e s s  
risk  for CIN . In addi t ion , she may coun s e l  the c lient about 
increased CIN risks bas ed on the c l i en t ' s environmen t a l  
f ac t ors, such as  dura t ion of oral con tracept ive us e ,  c l ien t 
immuno logical sys tem ( infect ion suscept ibi li ty) and c l ien t 
l i f e s tyle . Included w i th coun s e l ing , i s  the importance 
for  the nurs e  practitioner to provide the cl ient with 
contra�eptive alternatives and support in her compl iance 
with regular health care f o l low-up . 
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The nur s e  practitioner must practice with a knowledge 
of ep i�emio logical and s ystems factors that may inhibit 
the client's achievement of optima l function ing . She must 
have an awareness of the active process  of change and the 
spectrum o f  d i s ease in relation to normal and abnorma� 
patho logy of cervical tis sue . She must also  have an aware­
n e s s  of the interacti on of man's per sonal, bio logica l and 
social  sy stems along the developmenta l continuum . 
The nur se  practitioner in her expanded role  provides 
primary health care for the gyneco logy c l ient . She i s  
r esponsible for  perf orming a thorough hi story and phy s ical 
examination, prescr ibing the appropr iate oral contraceptive, 
obtaining cyto logical smears, and reviewing laboratory 
r eports . To promote the we l l-being and provide f or the 
needs of her c l ients, the nur se  practitioner needs an under­
standing of the dif ferenti a l  e f f ects of the estrogen and 
progestogen components of oral contraceptives .  The nur s e  
practitioner a l s o  needs t o  b e  able  t o  take into a6count 
how the interaction of agent ( oral contraceptive), host 
( c l i ent) and the environment ( the c l i ent's biopsycho social 
and cultural environment) influence health outcomes .  
In  summary, nurs ing and epidemio logy share in the goal 
to understand the relationship between factors  that af fect 
d i s ease occurrence . Both .cons ider time , plac e ,  person , 
host , agent , environment , and the spectrum of disea s e  
in order t o  plan hea lth promotion strategies  for c l ients . 
The Systems - in - Change model  provides an approach to a s s es s 
the c l ient ' s  sy stems and alteration s in equ i l ibr ium . 
Epidemio logical concepts provide too l s  for evaluation of 
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the f actor s  invo lved in the deve lopment of disease . Nur s ing 
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r e s earch concerning the r elationship between CIN and oral 
contraceptives utiL i z e s  an epidemio logical approach . Thi s  
information provides  a bas i s  f o r  the deve lopment and eva l -
uation of preventive procedures and public hea lth practice , 
such as coun s e l ing and cyto logical screen ing . An under� 
standing of potentia l ly s er ious effects of estrogen and 
proge sterone provides inf ormation that can a s s ist the nur s e  
practitioner i n  h e r  del ivery o f  optimum care t o  c l i ents 
with gyneco logical needs . 
CHAPTER TWO 
Literature Review 
The study of intraepithe lial  neoplasia of the uterine 
cervix ( C IN) and oral contraceptive use  nece s s itate s an 
under standing o f  the l iterature concerning CIN , the 
inf luence o f  estrogen s and progestogens on cervical t i s s ue 
changes , and an under standing o f  the risk  factors that are 
a s s oc iated with cervical cancer . The l iterature review 
inc ludes inf ormation on thes e  three topics . Section one 
contains information on CIN and screening methods , s ection 
two addresses  oral contraceptives and the inf luence of estro­
gens and progestogens on cervical tis sue change ,  and s ection 
three contains information on the factors which have been 
shown to be a s s oc iated with CIN . 
CIN and Screening Methods 
Cervical cancer is cons idered a maj or ma l ignant neo­
plasm of the f emale genital tract and it ranks �ixth as 
the cause of cancer deaths in women . The f requency of 
cervical cancer in young women has r i s en s ign i f icantly 
which suggests an increas e  in early exposure to carc inogenic 
influences ( Robbins and Cotran , 1 9 7 9 ) . The inc idence of 
cervical cancer increases  sharply to approximately 30 years 
of age , and it peaks at approximately 40 to 50 y ears of 
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age ( Cramer , 1 9 8 2 ) .  
M e i s els , et al . ( 1 9 7 7 )  f ound that the prevalence rate 
for CIN was highest in women between the ages of 15 to 44 
y ears , with a mean of 30 . 5  y ears f ollowed by a gradual 
decline with age .  The prevalence rate of CIN in women 
who have had cytological smears during screening is 1 . 1  
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to 1 . 6 cases per 100 women . The rate for carc inoma in s itu 
o f  the cervix i s  0 . 2  to 0 . 4 cases  per 100 women screened 
( Stern , 1 969 ) . The decrea s e  in deaths from cervical cancer 
is due to the early detection of curable le s i ons . Dur ing 
the 1 960's only 20 percent ( 20 . 0%) of cervical cancers were 
detected in the in s itu stage . Currently , 50 percent ( 50 . 0% )  
o f  cervical cancers are detected at an early stage of  
development . 
The increas e in early detection is  primar ily due to 
the development of  the cytological screening test . Cyto­
logical smears are recommended for all women beg inning at 
20 y ears of age and earlier if women are sexually active . 
Cytological smears are routinely performed on all women 
who request, and are us ing oral contraceptive prescr iptions . 
Although there are a certain number of  false pos itive and 
f alse  negative cytological smear reports , they have been 
f ound to be at least 90 percent ( 90 . 0% )  e f f ective in 
detecting cervical carc inomas and CIN ( Ho f fk in and Soost , 
1 9 8 1 ) .  The s quamocolumnar j unction at the cervix i s  the 
s i t e  where mo s t  cervical carcinomas ar i s e . Thi s  is  the 
area where the cytological smear is taken ( Robbins and 
Cotran , 1 9 7 9 )  .. and where spec ial a t ten t ion i s  given during 
colpo scopic examinat ion . 
The colpo scopic examina t ion is  performed on women who 
have an abnormal cy t ological smear . Thi s examinat ion 
increases the accuracy of  diagno s i s , decreases the need 
for biopsy , and i t  can lead t o  more f ocused CIN trea tmen t s  
f o r  the pat i en t /cli en t .  Colposcopy was f i r s t  introduced 
in 1 9 25. The colpo scope is a s tereoscopic binocular 
micro scope wi th 10 levels of magn if ication tha t u t ili z e s  
s pecial direc t and indirect coloring procedures  to detect 
and iden t i f y  cell changes on the cervix and vaginal mucosa 
( Fogel and Woods , 1 9 8 1 ) .  
2 1  
The developmen t o f  CIN and cancer of  the cervix occurs 
on a cont inuum of morphological abnormal i t ie s . Thes e  
abnormal i t i e s  progre s s  f rom normal t i s sue to reac t ive changes 
and inflamma t ion , squamous me tapla s i a ,  then mild , moderate 
and s evere dysplas ia , end ing in carc inoma in s i tu .  Condylomas 
are also included as  ano ther en t i ty in the con t inuum of  
C IN ( Robbins and Co tran , 1 9 7 9 ; �igure 1 ) .  Invas ive_ cervical 
carc inomas ar i s e  almos t  exclus ively f rom CIN les i ons . 
Norma l 
CIN 
Grade I 
Grade II 
Grade III 
Natura l Hi story o f  Precancerous Les ions 
of the Uter ine Cervix 
? 
�----� I I I I 
Atypia CIN 
Grade I 
CIN 
Grade II 
CIN 
Grade III 
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INVASIVE 
CARCINOMA 
Cervical intraepithe lial  neoplas ia used for the 
entire morpho logical spectrum o f  precursor les ions 
mi ld dy splasia 
intermediate les ions ( moderate dy splasia ) 
class ical carc inoma in s itu and s evere dysplasia 
Figure 1 
Diagrammatic Repres entation of  Several Poss ible Pathway s 
o f  Progress ion or Regress ion of  Intraepithe lial  
Cancerous Events in  the Uterine Cervix 
( Kos s ,  1 9 7 8 ) 
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It i s  important t o  note that there are a var iety o f  
alterations o f  the cervical epithelium which are benign . 
Thes e  benign alterations include repair following trauma 
which results in regeneration and proliferation of cells 
( hyperplas ia ) . Benign changes also include chronic 
cervicitis and s quamous metaplas i a  of  the endocervical 
glands that are not a s s oc iated with dyspla s i a .  When an 
epithelial.alteration develops on the external cervical 
surface due to an eros ion of the vulnerable columnar 
epithelium that may have grown at that s ite , estrogenic 
stimulation initiates reepithelialization by the stratif i ed 
squamous epithelium ( ectocervical epithelium ) .  The alter­
ation is covered by negenerati�e epithelium which grows 
over it from the outs ide and upward . With progestogenic 
stimulation , the reserve cells beneath the columnar 
epithelium o f  the endocervix prol:t'f erate in the form o f  
res erve cell hyperpla s ia . Res erve cell hyperplas ia pre­
ce�es  the regeneration of  the squamous epithelium which 
constitutes the epithelium of the ectocervix 
( Dallenbach-Hellweg , 1 9 8 1 ) .  Res erve cell hyperplasia  
spreading over the defect undergoes maturation through the 
process  of s quamous metaplas i a . Up to thi s  po int the repair 
processes  have been benign . However , in the last stage 
of maturation,  a percentage of the cases do not proceed 
smoothly from reepitheliali z ation to normal maturation .  
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In these s ituations , precancerous le s i ons of  various grades 
develop . The s e  include a var iety of  levels of  dysplas i a ,  
carc inoma i n  s itu and condyloma; 
C ondyloma ( Human Papilloma Virus-HPV ) are included 
in the continuum of CIN ( Ko s s , 198 3 ) .  They are flat 
papillar les i ons of the genitalia that have been known for 
c enturies . Viral etiology of  these warts , which are usually 
s exually transmitted , has been well documented ( Mei s els , 
et al . ,  1 9 8 3 ) .  Thes e  les ions are an important factor 
cons idered to be respons ible for at least some of the pre ­
cancerous changes  of  cervical tis sue ( Ko s s , 1 9 83 ) . Though 
not all condylomas progr e s s  to more advanced les ions , 
malignant trans formations o f  genital warts have been docu­
mented ( Mei s els and Morin , 1 9 8 1 ) .  
C ervical condylomas have o ften been mi staken for 
dysplasia ( Me i s els , Fortin and Roy , 1 9 7 7 ) .  In a review 
of previously diagno s ed dysplas ias , more than 70 percent 
( 70 . 0% )  were f ound to be condylomas ( Mei s els , et al . , 1 9 7 7 ) .  
Syrj anen ( 1 9 7 9 ) reported that condylomatous le s i ons were 
present in 49 . 4  percent ( 49 . 4% )  of patients with dy spla s ia 
and neoplastic les ions . O f  the s e  condylomas ,  8 8 . 1  percent 
( 8 8 . 1% )  were pres ent in women who were le s s  than 40 years 
o f  age . Of  the f our types of  condylomas ,  the flat type 
is the mo st common one found on the cervix and it is the 
mo st common les ion of the cervical epithelium of the teenage 
woman ( Ko s s , 1 9 8 3 ) .  
Oral Contraceptives and the In fluence of  Estrogen s  
and Progestogens on CIN 
Dallenbach-Hellweg ( 1 9 8 1 )  found that oral contracep-
tives may cause  alterations of  the cervical epithelium . 
Therefore , it i s  important to cons ider the estrogen and 
progestogen influence on CIN . Although estrogens and 
progestogens were f i r st is olated and synthes i z ed during 
the 1940 ' s ,  they were not used therapeutically until f ive 
y ears later. In itially , estrogens and progestogens were 
used for the treatment of reproductive d i sorders and for 
d i s s eminated cancer . S ince the 1 960 ' s ,  the primary use 
o f  'e strogens and progestogens has been for contraception 
( Beral , 1 9 80 ) . 
The mo st commonly used oral contraceptives include 
both estrogen and proge stogen . Progestogen i s  an "agent 
capable o f  produc ing biological e f fects s imilar to thos e  
o f  progesterone" ( Stedman ' s ,  1 9 7 6 ) . - The combination of  
estrogen and progestogen in oral contraceptives inhibit 
ovulation by suppr e s s ion of gonadotropins follicle stimu­
lating hormone ( FS H )  and lutein i z ing hormone ( LH ) . They 
also stimulate alterations in the cervical mucus and 
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endometrium ( Kastrup , 1 9 83 ) . There are  many brands o f  oral 
contraceptive s which are compos ed of  d i f f erent dosages and 
types of estrogens and progestogens . 
E s t rogens and proges togens in oral contracept ives act 
speci fical ly on the men s t rual cyc l e . E s trogens suppre s s  
FSH , block f o l l icular deve lopment for ovulat ion , and they 
s t imulate the pro l i f erat ion of the s tratified s quamous 
epi thelium of the ectocervix . Progestogen suppre s s e s  LH 
secret ion to inhibi t ovulation.  Proge s t ogens s t imulate 
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the co lumnar epi the l ium and the reserve c e l l s  beneath i t  
( Da l l enbach-Hel lweg , 1 9 8 1 ) .  Ober ( 1 9 7 7 )  repo r t s  tha t· 
s t imulat ion o f  g landular hyper secre t ion i s  the mos t  commonly 
f ound effect  of  proges t ogen . In addi t ion , he has no t ed 
tha t proges togen a l t ers  the cervical mucus by modi f y ing 
the normal pro te in pa t t ern which caus es  i t  to thicken , and 
i t  s t imulates  c lumping and fo lding of epi the l i a l  cells . 
Proges togens cause a d i s turbance in the endome tr ium which 
makes i t  unsuitable for implantat ion of a f er t i l i z ed ovum 
( Dong and Eof f , 1 9 7 8 ) .  
The e f f ec t  of  the exogenous e s trogens and prog e s t ogens 
depends great l y  on the ma tur i t y  of the cervical epi thel ium 
a t  the t ime they are inge s ted . Es t rogen may induce 
c e l lular matura t ion . Proges t ogen may inhibi t c e l lular 
maturation and/or induce an increase in desquama t ion of 
the cervical epithel ium ( Wied , e t  a l . ,  1 9 8 3 ) .  The 
endocrino logic cond i t ion of the c l ient and the dosage 
and s truc ture of  the es trogen and proges togen prepara t ion,  
determine whe ther the hormones wi l l  ac t antagoni s t ica l ly 
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or synerg istically ( Wied , et al . ,  1 9 83 ) . 
Kamal ( 1 966 ) studied the eff ects of d i f ferent combi­
nations of e strogen and progestogen on the endometrium and 
cetvical mucosa . He f ound that pills with a higher content 
o f  progestogen had a weak estrogen and strong progestogen 
e f f ect which could lead to breakthrough bleeding , weight 
gain , and scanty mens e s . P ills with a lower content of  
progestogen tended to increase the amount and length of  
menstrual flow . Other s ide e f f ects as sociated with a 
higher content o f  e strogen in pills include naus ea , fluid 
retention , breast tenderne s s , headache , hypertension ,  
dysmenorrhea , f ibroid growth , and leukorrhea ( Wrenn , 1 9 79 ) . 
H igher content o f  progestogen is  also associated with 
irr itability , headache , depr e s s ion , and occasionally 
hypertens ion ( Wrenn , 1 9 79 ) . Because  estrogens used alone can 
o ften cau s e  irregular , prolonged , and unpredictable menstrual 
bleeding patterns , it i s  neces sary to use a combination of  
progestogen with the estrogen ( Wrenn , 1 9 79 ) . 
Var iables Assoc iated with CIN 
Beginning in the early 1 9 50's and extend ing through 
the 1 960's , cons iderable res earch was conducted which helped 
to clar ify r i sk factors and demographic var iables  as sociated 
with cervical cancer . The age of f i r st coitus and multiple 
s exual partners were two important variables  found to be 
a s s oc iated with C IN . Rotkin ( 1 98 1 )  stated that thes e  two 
variables showed the s tronges t epidemiological rela t ion­
ship foBnd wi th cervical cancer . Ro tkin also  s tated tha t 
in all popula t ions where early coitus is  widespread , there 
is a high degree of  cervical cancer . It  is  believed tha t 
a high degree o f  cellular ac t ivity exis t s  during adoles­
cence which provides maximal oppor tun i ty for the oncogenic 
tran s f orma t i on of cervical cells ( Ro tkin , 1 9 7 2 ) . Ro tkin 
repor ted tha t the increa s ed r i sk of  cervical cancer may 
2 8  
b e  relat ed to a combina t ion of  demographic , epidemiological, 
e t i ological and pa thological interac t ions . 
Research indica t e s  that carcinogenesis  requires a 
combinat ion o f  available vulnerable t i s sue , the applica t i on 
o f  a carcinogen , and a la t en t  period (Rotkin , 1 9 8 1 ) .  The 
nature of the carcinogenic componen t is not  fully under­
s tood . Ro tkin provided an exten s ive li s t  of propos ed 
. var iables tha t have been s tudi ed for  their  rela t ionship 
t o  the r i sk of cervical cancer ( Ro tkin , 1 9 8 1; Append ix B ) . 
Kes sler ( 1 9 8 1 ) s ta ted that there are several well accepted 
variables in cervical cancer epidemiology . These  var iables 
include a "nonwhi te" mortality  r i sk which is  twice tha t 
o f  the whi t e  popula t ion , and a mortali ty r i sk for the total 
population which is  one half of  tha t which ex i s t ed in 1 960 
for c ervical cancer . Thi s  decrease in mor tali ty can be 
e xplained by the increase in early detect ion and trea tmen t 
o f  cervical cancer . 
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Among the many risk factors as sociated with CIN and 
cervical cancer is condyloma . Ko s s  ( 1 9 8 3 ) stated that there 
is "excellent evidence" that flat condylomas may per s i st 
in a s ignif i cant proportion of  women and become assoc iated 
with intraepithe l i al neoplasms or invas ive cancer . Many 
cases of condyloma have been found to coexist with an 
adj acent dy splas ia or carc inoma in s itu . Me i s e l s  and Morin 
( 1 98 1 )  found that 25 . 6  percent ( 2 5 . 6% )  of  the condyloma s 
were associ ated with dysplasia  and neopla st ic lesions . 
Me i s els and Morin ( 1 9 8 1 ) stated that condylomas precede 
dy splasia by 3 . 3  year s , carc inoma in s itu by 9 . 3  years and 
invas ive cancer by 2 7  y ears . Therefore , condyloma may act 
as an initiating or promoting agent of abnormal cervical 
tis sue changes . 
Not all condylomas progre s s  to more advanced les ions 
and many regre s s  which indicates the pos s ibility of  other 
promoting f actors  that may be neces s ary for malignant trans­
formation . Host resi stance may play an important role in 
the development of malignant trans f ormations . The presence 
and per s i stence of  the Human Papilloma Virus in the genital 
tract of immuno suppre s s ed women over many years has been 
c ited and a s s oc i ated with precancerous les i ons that led 
to invas ive carc inoma ( Tabibzadeh , et al . ,  1 9 8 1 ) .  Oral 
contraceptives may also  be promoting factors of condyloma 
in C IN , although this  has not been investigated . 
The role o f  oral contraceptive s in cervical cancer 
i s  still unclear , however they have been a s sociated with 
CIN . Most o f  the res earch involving oral contraceptive s 
has focused on a compar i s on of  oral contraceptive users 
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and nonusers rather than on the e f f ects of  the individual 
oral contraceptive preparations . A number of  factors have 
a f f ected and complicated the user versus nonuser studies , 
such as  the f inding that oral contraceptive users tend to 
be more s exually active than nonus ers ( Lilienf eld , 1980 ) . 
The more s exually active population i s  f requently correlated 
with a higher r i sk and inc idence of cervical dyspla s ia which 
complicates evaluation of the relationship between oral 
contraceptive s and cervical tis sue changes ( Rotkin , 1 9 8 1 ) .  
Oral contraceptive users also  have a higher f requency of  
y early cytological smears , therefore , they are  more likely 
to have early recognition of cervical tissue changes ( Swan 
and Petitti , 1 9 8 2 ) .  Diff erent proge stogen and estrogen 
strengths may also  have d i f ferent cytological e f f ects on 
the contracept ive user , which are not accounted for in 
studies  compar ing users of d i f ferent contraceptive methods . 
S andmire , et al . ( 1 9 76)  stated that studies of  CIN 
are o ften bas ed on cytology alone and conclusions are drawn 
without tis sue examination . Duration of oral contraceptive 
usage and the f ollow-up period is often inadequately studied 
when one cons iders the latent period involved in 
carc inogenes i s . Lilienf eld ( 1 9 80 ) stated that method­
olog ical problems are pres ent in stud ies of  oral contra­
ceptives and cervical cancer because prior to beginning 
the use of contraceptives , women may have d i f ferent risk 
f actors for cervical cancer . Therefore , results o f  the 
stud i e s  may be totally unrelated to the contraceptive 
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method util i z ed . Stern , et al . ( 1 970 ) found that even 
before they started taking oral contraceptives ,  women who 
cho s e  the "pill" in the early 1 960 ' s  were more likely than 
intrauterine device (IUD) user s  to have abnormal cytological 
smears .  Factors such as the number of  s exual partners and 
the amount of  sexual activity may have influenced the cho ice 
of contraceptive . 
M e i s els , et al . ( 1 9 7 7 ) studi ed the age at f irst coitus 
and its relationship to oral contraceptive us e .  He found 
highly s ignif icant correlations between early onset o f  
s exual activity and dysplasia , oral contraceptive u s e  and 
dyspla s ia , and early age of co itus and oral contraceptive 
us e .  After correcting for the age at f irst coitus , the 
res earcher s  noted an excess  of dy splasias  among oral contra­
c eptive user s . 
Swan and Brown ( 1 9 8 1 ) in the ir study of  the interaction 
of oral contraceptive us e ,  s exual activity and cervical 
cancer , attempted to match oral contraceptive users with 
nonus ers .  Although no s igni f i cant relative r i sk of  cervical 
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cancer .was found among oral contraceptive users , their 
study was  s omewhat biased becau se  the cytological smear 
interval was longer for nonuser s , and the oral contraceptive 
clients had twice as many sexual partners as the contro l  
group . Swan and Brown ( 1 9 8 1 ) found that the mo st increa s ed 
r i sk of  cervical cancer occurred among women who were more 
s exually active and who had been u s ing oral contraceptives 
f rom four to s ix year s . 
O ry, et al . ( 1 9 7 6 )  compared the risk o f  cervical cancer 
in oral contraceptive users to the r i sk in IUD users . 
Although they d id not report cervical carc inoma more 
f requently in the oral contraceptive users , they did find 
that at the time of  choos ing oral contraceptives ,  women 
with one cytologic smear had f ewer carc inoma in s itu 
f indings than IUD users . However, in established oral 
contraceptive users  with one cytologic smear in which the 
duration o f  oral contraceptive u s e  was not reported, there 
was a 40 percent ( 40 . 0% )  higher risk of dy spla s ia as compared 
to IUD users . In contraceptive users with two cytologic 
smears, there was a 50 percent ( 50. 0% ) increased risk o f  
dy splasia among oral contraceptive users as  compared with 
IUD u s er s . The two cytolog ic smears are ind icative of a 
longer duration of  contraceptive use . 
D allenbach-Hellweg ( 1 9 8 1 )  stated that prolonged 
increase in proliferative activity provides an opportunity 
for the man i f estation of the e f f ects of carc inogenic 
substances. The potential ef fects of  risk factors 
a s s oc iated with estrogen and progestogen us e ,  and multiple 
s exual partners , may be increa s ed dur ing the proliferation 
of  c ervical epithelium which is ass ociated with spec i f ic 
hormonal properties in contraceptives. 
S inger and Jordan ( 1 9 7 7 )  reported that the combined 
e strogen and progestogen pill may be directly as sociated 
with cervical neoplasms because  the p i l l  can lead to an 
increase in s quamous metaplas ia. An ever s ion of the endo ­
cervical columnar epithelium , when expo sed to the vaginal 
environment and pH , induces the metaplastic trans formation 
which is  s ometimes as sociated with cervical precancerous 
changes. Mingeot and Fievez ( 1 9 7 4 )  compared biops ies  
o f  patients who were taking three d i f ferent estrogen and 
progestogen combinations. They f ound that endocervical 
epithelium does appear to undergo important changes when 
it is under · synthetic estrogen and progestogen inf luence. 
They also c ite an increa s e  in the f requency of  metaplas i a. 
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Rubio ( 1 9 7 7 )  reported an increas ed maturation o f  
s quamous cells which are a s s oc iated with c irculating 
estrogen. He empha s i z ed the need for further investigation 
o f  poss ible associations between oral contraceptives and 
cervical atypias. 
S tudies  have been conducted on the relationship 
between exogenous estrogen and cervical cancer. U s e  of  
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the e s trogen d i e thyls t ilbes trol ( DES ) in utero has been 
as socia ted w i th increas ed f requency of abnormal cy tological 
smears and an increas ed risk of  cervical cancer ( Lilienfeld , 
1 9 80 ) . Bibbo , e t  al . ( 1 9 7 7 )  s tudied women expo sed to DES 
during pregnancy . The drug was randomly a s s igned to one 
group and a placebo was g iven to the o ther . group . A 25  
y ear follow-up s tudy showed tha t cervical cancer occurred 
in one percen t ( 1 . 0% )  of the expo s ed group as compared to 
0 . 4 percent ( 0 . 4% )  of the unexpo sed group . The prevalence 
rate for cervical cancer for  the general popula t ion is 0 . 2  
t o  0 . 4  per 100 women screened ( S tern , 1969 ) . Although 
Boyc e , e t  al . ( 1 9 7 7 ) in their s tudy of the e s t rogen component 
o f  the "pill" and i t s  rela t i onship to cervical cancer found 
no as sociat ion,  o ther res earch f indings indicate the 
poten t ial increased r i sk of cervical cancer in premenopausal 
women us ing es trogen ( Rubio ,  1 9 7 7 ;  L ilienfeld , 1980 ; 
B ibbo , e t  al . ,  1 9 7 7 ) .  
P roges togen is  also involved in cervical t i s sue changes 
and it  has been s tud i ed for its  a s s ociat ion wi th the r i sk 
o f  cervical cancer . S z ontagn ' s  ( 1966 ) s tudy of  prog e s t ogen 
c i t ed the d i f f erences  in endome trial and cervical mucus 
e f f e c t s  be tween dosages of 2 . 5  to 2 . 0 mg . and 1 . 0 to 1 . 5  mg . 
o f  prog�s togen .  H i s  s tudy showed tha t the combina t ion of  
e s trogen. wi th proges togen tends to negate the potent e f f ec t  
o f  proges togen o n  the cervical mucus . A number of  s tudies  
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have shown a n  increased r i s k  of  cervical cancer i n  women 
u s ing the inj ec table proges terone medroxyproges terone 
ace tate  ( Depo-Provera or DMPA) ( IARC Working Group , 1 9 7 4 ; 
Powell , 1 9 7 1 ) . In countries  where DMPA i s  f requen tly used , 
the incidence o f  cervical cancer is  high (iili�nfeld , 1980 ) . 
Dallenbach-Hellweg ( 1 9 8 1 ) made the observa tion that 
among young girls who had taken oral con tracept ives for 
the treatmen t of  skin diseas e ,  and who had never had inter­
cours e ,  the  incidence of  preneoplas t ic les ions was  higher 
than normal w i th the les ions tending to occur earlier in 
l i f e  than would normally be expec t ed .  Dallenbach-Hellweg 
( 19 8 1 ) also  f ound tha t the inc idence of adenomatous hyper­
pla s i a  of  the cervical mucosa was f our t imes higher in women 
t aking high proges togen pills and pure proges togen produc t s . 
Although in 1 9 8 1  Dallenbach-Hellweg repor t ed that adeno­
carc inoma was s omewhat uncommon , Ng repor ted in 1983  tha t 
the two types o f  carcinoma o f  the u t erine cervix are 
s quamous cell carc inoma ( es trogen respons ive s quamous 
epi thelial c ell s )  and adenocarcinoma ( from proges terone 
respons ive endocervical columnar epi thelium ) . Ng ( 1 9 8 3 )  
reported that dur ing the per iod 1 940 to 1 9 7 4 , there · was 
a decrease in · the inc idence of  squamous cell carcinoma and 
an increas e  in adenocarc inoma . A definite  correla t ion 
be tween adenoma tous hyperpla s ia and adenocarcinoma in s i tu 
and the in t ake of  oral con tracept ives has been found by 
a number o f  o ther res earchers ( Maqueo, e t  al . ,  1 966; 
Taylor , e t  al . ,  1 967; Candy and Abell, 1 968; Mingeot and 
Fieve z, 1 9 7 4 ) . Dallenbach-Hellweg ( 1 9 8 1 )  reported tha t 
between 80 to 100 percent ( 80 . 0  to 100 . 0% )  of the women 
wi th adenohyperplas i a  of the endocervical mucosa had been 
t aking oral contracep t ives . 
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According to the Dallenbach-Hellweg s tudy ( 1 98 1 )  there 
may be evidence to s uspect an e t iolog ical link be tween 
proges togen adminis trat ion and adenocarcinoma of the endo­
cervix . The proge s t ogen produced implicated in the "p ill" 
i s  the highly potent hormone norges trel . This  s tudy showed 
that all of the clients w i th adenocarcinoma of the endo­
cervix had t aken oral contracept ives containing norges trel . 
Following s everal years of  s tudy of  the effects  of  
oral contracep t ives , Dallenbach-Hellweg ( 1 9 8 1 ) f ound an 
a·pparent predominance of cervical intraepi thelial neoplas ia 
which was derived f rom s tr a t i f ied s quamous epi thelium among 
tho s e  women who had taken high es trogen pills . Cervical 
neoplas ias , der ived f rom reserve cells which are s t imula t ed 
by proges terone , were more prominent among clients  who had 
t aken high proges togen produc t s . Dallenbach-Hellweg ' s  
s ta t i s t ical analy s i s  of  a large series of  women revealed 
an increas ed incidence of C IN among women who u sed oral 
contracept ive s and in the younger age groups . Dallenbach­
He}lweg found tha t precancerous changes  in women who used 
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oral contracept ives occurred 1 0  y ears earlier than i n  tho se  
who were no t us ing them . According to the Dallenbach- Hellweg 
study ( 1 98 1 ) , oral contraceptives affec ted maturation and 
accelerated the appearance · of  precancerous cervical tissue 
changes . 
S tern, et al . ( 1 9 7 7 )  repor ted that 30 percent ( 30. 0% )  
o f  the oral contraceptive users w i th dyspla s ia progre s sed 
to cervical carcinoma in s i tu as compared wi th f ive percent 
( 5 . 0% )  o f  thos e  not us ing the "p ill . "  The res earchers 
indicated tha t  oral contracept ive s may accelerate  the ra t e  
o f  progres s i on f rom dy splasia  to carc inoma i n  s itu . Rather 
than a direct e t iological link to cervical dyspla s ia , this 
progress ion may be as sociated w i th an alt erat ion of the 
woman's immunological sys tem . Beral ( 1980 ) states that 
i t  i s  pos s ible that certa in estrogen-progestogen combinations 
in the combined "pill" may induce cancer where other combi­
na t i ons might suppr e s s  i t . Because the endogenous hormonal 
status of the cli en t  is cons idered important in all cancer 
r i sk ,  reproductive trac t cancers are more likely to be 
as sociated wi th complex hormonal rela tionships . Endogenous 
hormonal influences may vary in nullipara , multipara, and 
menopausal women , and women with an early age of menarche . 
Beral ( 1980 ) sta ted that the mo s t  impor tant way in which 
the exogenous e s t rogens and progestogens may af f ect cancer 
r i sk is by altering the hormonal balance which affec t s  the 
me taboli sm, immune re sponse  and the en t ire homeo s ta t ic 
mechan i sm . 
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Although s tudies  have not  been able to cons ider all o f  
the variables involved i n  the rela tionship be tween oral 
con tracep t ive use  and cervical carcinoma, res earch f indings 
sugg e s t  tha t oral contracept ive use, especially long- term 
use, may increase the risk  of cervical carcinoma . Ory, 
et al . ( 1 9 7 7 )  and Per i t z, et al . ( 1 9 7 7 )  have found an 
increased c ervical cancer risk  in long- term oral con tra­
cept ive usage . In s tudies  of  dura t ion o f  oral contra­
cep t ive use, o ther . confounding variables have fewer indirect 
e f f ec t s  ( Lilien f eld, 1 9 80 ) . 
Ory, e t  al . ( 1 9 7 7 )  s tudi ed a black popula tion of  6 , 663 
IUD users  and 14 , 447  oral con tracept ive users . The 
researchers found that the rela t ive risk  for carcinoma in 
s i tu increased f rom 2 . 5  for one t o  two years of oral con tra­
cept ive use to 4 . 7  for  three or more y ears of  oral con tra­
cept ive usage . Wor th, et al . ( 1 9 7 2 )  and Boyce, et al . ( 1 9 7 7 )  
also  repor t ed tha t a larger number of  long dura t ion oral 
con tracept ive users were as socia ted w i th cervical carcinoma 
in s i tu .  Melamed and Flehinger ( 19 7 3 )  found tha t the 
rela t ive r i s k  for cervical cancer was increased 1 . 5  in oral 
con t racept ive user s  as  compared w i th diaphragm users, and 
0 . 8  as compared w i th IUD user s . Per i t z, e t  al . ( 1 9 7 7 )  s tudied 
1 8 , 000 women and adj us ted s tudy f indings for age, education, 
mar ital status , number of  cyto logical smears and relig ion . 
He compared duration of  oral contraceptive users of les s  
than two years with users of  other contraceptive methods 
of les s  than two years . He found a re lative risk  for oral 
contraceptive users of 2 . 4 .  For two to four years of oral 
contraceptive use , he f ound a relative risk  of 3 . 0 ,  and 
for four or more y ears o f  oral contraceptive us e ,  he found 
a relative r i s k  of  4 . 1 .  
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S wan and Brown ( 1 9 8 1 )  stud ied 69 patients with cervical 
cancer and 2 16 matched control subj ects . They found a trend 
in the r i s k  o f  cervical cancer which was ass ociated with 
the duration of oral contraceptive u s e .  Short-term oral 
contraceptive users had a slight increase in re lative risk  
o f  cervical cancer which gradually increased with a maximum 
of f our to s ix years of oral contraceptive us e .  The cervical 
cancer risk  gradually declined in over s ix years duration 
of oral contraceptive us e .  Swan and Brown ( 1 9 8 1 )  concluded 
that oral contraceptive users with a median duration o f  
f our t o  s ix y ears usage were a t  the highest r i s k  f o r  cervical 
cancer ( s ignif icance p < 0 . 0 5 ) . Sandmire , et al . ( 1 976)  
als o  c ited r i s ks with the duration o f  oral contraceptive 
use . They studi ed 76 subj ects with cervical carcinoma and 
compared them with 7 80 contro l  subj ects . They also compared 
IUD users with oral contraceptive users for risks  of  cervical 
cancer . They found no increased r i s k  between the two groups 
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with the exception of  an increased risk for cervical cancer 
in the oral contraceptive users of three to s ix years 
duration .  N o  other a s s ociations for cervical cancer r i sk 
were found in the ir study . 
In . one o f  the most recent studi e s  of  the relationship 
between oral contraceptives , duration of  us e ,  and cervical 
cancer (Ves sey , et al . ,  1 9 8 3 ) , both carc inoma in s itu and 
dysplas ia occurred more frequently in the oral contraceptive 
group than in the IUD group . Of 13 cases of invas ive cancer , 
nine cases  had more than 1 3  y ears use of  oral contraceptives .  
Duration o f  oral contraceptive use was s ignif icantly 
correlated with the r i sk of  cervical cancer . The inc idence 
for  cervical dy spla s ia , carcinoma in s itu , and invas ive 
c ervical cancer combined rose  f rom 0 . 9  per 1000 woman years 
in thos e  with up to nine years of oral contraceptive use 
to 2. 2 per 1000 woman y ears in tho s e  with more than e ight 
y ears of oral contraceptive us e .  No such trend in incidence 
with · duration of use  was noted among the IUD users . 
Although Ves sey , et al . ( 19 8 3 ) found no s ignif icant 
a s s oc iations with spec i f ic estrogens or progestogens or 
with any particular dose  or brand of oral contraceptive , 
a high proportion of  the oral contraceptive use  in the study 
was r elated to products containing 50 mg . or more of  
estrogen .  
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S ummary 
In l s ummary , the development o f  CIN and carcinoma of 
the c ervix occur s on a c ontinuum of  morphological abnor­
malities . Early detection o f  curable les i on s  with the 
cytological smear , and accuracy of  diagnos i s  and improve­
ment of treatment with colposcopy have been as sociated with 
a decreased mortality r i sk from cervical cancer . The 
s ignif icant r i s e  in the r i sk o f  cervical cancer in younger 
women suggests an increase in early exposure to carcinogenic 
influences . Many variables  have been studied to examine 
the carcinogenic influences  and the ir relationship to the 
r i sk o f  c ervical cancer ( Rotkin , 19 8 1 ) .  Among these 
vari ables are oral contraceptives compos ed o f  estrogens 
and progestogen s . Studies have found that these hormones 
may influence the proce s s e s  of  regeneration and 
r eepitheliali z ation of cervical eros ions ( Dallenbach-Hellweg , 
1 9 8 1 : Wied , et al . ,  1 9 83 ) . Stern , et al . ( 1 9 7 7 )  and Beral 
( 1 9 8 0 )  indicated that oral contraceptive s may increase the 
rate o f  progre s s ion f rom cervical dy splasia  to carc inoma 
in s itu by a f fecting the woman ' s  hormonal balance . The 
spec i f ic oral contraceptive and the duration o f  oral contra­
ceptive u s e  may also  have a s ignificant e f f ect on the 
development of CIN . A number of studies  have shown that 
exogenous e strogens may be as soc iated with an increased 
r i sk o f  cervical cancer ( Lilienfeld , 1980 ; Rubio , 1 9 7 7 ; 
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Bibbo , e t  al . ,  1977;  S tern , 1 9 70 ) . Cervical cancer r i sk ,  
espec ially adenocarcinoma r i sk ,  has also been associa ted 
w i th proges togen use ( Dallenbach-Hellweg , 1 9 8 1; IARC Working 
Group , 1 9 7 4; Powell , 19 7 1 ) .  Many of these  s tud ies found 
s ign i f ican t a s s ociat ions be tween oral contracept ives and 
CIN . 
Most  o f  the res earch involving oral con tracept ives 
and cervical cancer has focused on a compari s on of  oral 
con tracept ive users wi th nonuser s ,  ra ther than on the e f f ec t s  
o f  the ind ividual oral con tracept ive prepara tion s . The se  
comparison s tud ies  have been complicated by  o ther factors 
s uch as  d i f f erences in levels of  sexual ac t ivi ty or oral 
con tracept ive users as  compared w i th users of o ther con tra­
cept ive me thods . In addi t ion , mo s t  s tudies  have been based 
on cytological smear repor t s  ra ther than on more specific  
colposcopy t i s sue examination . 
M o s t  cancer r i sk is  rela ted to dose and dura tion of 
e xpo s ure t o  the carc inogen . Malignancy i s  not  expec ted 
un t il a cer tain la tency period has elaps ed . A number o f  
s tudi e s  have n o t ed a rela tionship be tween longer durat ion 
of exogenous es trogen and proges togen use and cervical 
cancer (Melamed and Flehinger , 1 9 7 3; Sandmire , e t  al . ,  
1 9 76; Ory , e t  al . ,  1 9 7 7; Peri t z ,  e t  al . ,  1 9 7 7 ;  Swan and 
Brown , 1981;  and Ves s ey , e t  al . ,  1 9 8 3 ) .  The associat ion 
be tw�en oral con tracept ives and condyloma of  the uterine 
c ervix has not been examined in the se  studies, however it 
may be an important var iable in the progress ion of  CIN . 
Lilienfeld ( 1 980 ) stated that confounding variables have 
f ewer indirect e f fects on the f indings in studies of  
duration o f  oral contraceptive use and CIN . 
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Further research on spec i f ic oral contraceptive 
preparations and the ir duration of use  is needed . Research 
in thi s  area should include CIN and condy loma which have 
been diagno s ed by colposcopy . Studies of  spec i f ic oral 
c ontraceptive preparations and the ir duration of  use could 
help to conf irm and clarify previous trends in studies which 
have focused on oral contraceptive users and nonusers . 
CHAPTER THREE 
Me thodo logy 
The purpose of  this s tudy was to determine the relat ion­
ship between spec i f ic oral contracept ives and CIN , and to 
determine if the duration of use  and con t ent of the oral 
c ontraceptive were re lated to CIN . Most  of  the research 
that has been conduc ted compared oral con tracep t ive users 
with nonus ers . Thes e  studies were concerned with the leve l 
o f  s exual act ivity ' o f  the con traceptive user , the dura t i on 
o f  con traceptive use , and other var iables as socia ted w i th 
the r i s k  o f  cervical cancer . Only a f ew of  the s e  s tudi es  
were  concerned with spec i f ic oral  con traceptive preparations , 
dur a t ion of  u s e , and cervical t i s sue changes . Condy loma , 
which is  a form o f  precursor cervical t i s sue change , and 
oral contracept ive u s e  have not received s u f f icient 
a ttention in s tudies re lated to the r i s k  of cervical cancer . 
In  an e f f ort  to obtain add i t ional informat ion con­
c ern ing the r i s k  of cervical cancer , this  s tudy inve s t igated 
spec i f ic oral con traceptive preparations , durat ion of  use , 
and the ir relationship to CIN . 
Research Des ign 
The research des ign for thi s  s tudy was a retrospect ive 
correlat ional des ign . Po l i t  and Hung ler ( 1 9 7 8 )  sta t ed tha t 
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retro spective and correlational res earch are e f fective in 
examinimg pres ent health problems and their link with events 
dr • phen®mena f rom the past . Lilienfeld ( 1 980 )  stated that 
retro spective correlational studies allow for the exami­
nation 0f  a s s ociations between the characteri stics of  
interest · and the condition or disease  being studied . The 
retro spective correlational study des ign was appropr iate 
for thi s  study which investigated oral contraceptives and 
duration o f  usage , and their relationship to CIN . 
Information for thi s  study was obtained from clinical 
records of clients who attended a colpo scopy clinic in a 
large univer s ity medical center located in a southeastern , 
metropolitan area of  the United States .  Client records 
were examined to obtain information on current d iagnosis  
o f  CIN , the clients ' past hi story o f  spec i f ic oral contra­
c eptive u s e , and duration o f  usage . Becaus e  of  study 
location and sample s i z e ,  study results cannot be 
generaliz ed .  
Population and Sample 
The study population included a convenience sample 
of 52 clinical records of clients who attended a colposcopy 
clinic from October 2 4 , 1 9 8 3  through March 6 ,  1 9 84 . The 
clients had been ref erred to the colposcopy clinical becau s e  
o f  abnormal findings o n  their cytological smear s . Only 
thos e  clinical records of clients who met the following 
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s tudy cri teria were included : ( 1 )  the client had been us ing 
one of the f ive oral contracept ives spec i f ied in the 
def ini t ion of t erms , ( 2 )  the client had been us ing the 
spec i f ic oral contracept ive cont inuously for a minimum o f  
s ix months prior to the f i r s t  clinic vi s i t , and ( 3 )  the 
oral contracept ive user was a newly referred client . 
S ampling began on Oc tober 24 , 1 9 8 3  and cont inued through 
March 6 ,  1984 . The colposcopy clinic nur s e  recorded the 
spec i f ic oral contracept ive , the duration of us e ,  and the 
clien t ' s  name on an inve s t igator-des igned data collec t i on 
f orm during the client ' s  ini t ial a t tendance a t  the colposcopy 
clinic (Append ix C ) . Nur ses  a s s i s ted client recall of  spe­
c i f ic oral contracep t ives by u t ili z ing a picture char t .  
Sampling was limi ted to the spec i f ied t ime per iod for data 
collec t i on . Dur ing this t ime period a to tal o f  52  client 
clinical records me t the cri teria for inclusion in the s tudy . 
S tudy S e t t ing 
The s tudy took place in a colposcopy clinic located 
in a large univer s i t y  medical c enter . The clinic served 
one maj or c i ty and many surrounding counties  and i t  was 
s ta f f ed by hospi tal s taff . Cli en t s  s een in this  clinic 
were referred from gynecology clinics and pr iva te phy s icians 
in the me t ropolitan c i ty and surrounding areas . The s tudy 
popula t ion included both pr iva t e  and public clinic clien t s  
f rom rural and urban areas . Clinics were conduc t ed each 
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Monday morning and Tuesday af ternoon . All clients received 
a colposcopic examina tion w i th a biopsy being performed 
when nece s s ary . 
Data was collec ted by the colposcopy clinic nurs e  while 
interviewing the client to obta in the medical his tory . 
Interviews were conduc t ed in a s emipriva te interviewing 
area prior to the colpo scopic examina t ion performed by the 
phy s ician .  
Da ta Collect ion Ins trument 
The da ta collec t ion ins trument u t ili zed in thi s  s tudy 
was an inves t iga tor-des igned , two -par t data collect ion form . 
The inves t igator developed the neces sary form based on review 
of the li t erature , pas t  clinical work exper i ence , and a 
pilot s tudy . Part one of  the form was comple ted by the 
colpo scopy clinic nur s e  and part two was completed by the 
inves t igator . 
The data collec t ion form was des igned to identify  the 
clinical records to be included in the s tudy and to provide 
for  individual obs erva t ions of spec i f ic oral contracept ives 
and diagnoses . Part one cons is ted of i tems to obtain the 
clinical record iden t i f icat ion of  the client , the spec i f ic 
oral contracept ive used , and the durat ion of  oral contra­
cep t ive us e .  Part two of  the data collec t ion form cons is ted 
of four · i tems cons truc t ed to obtain inf orma t ion rela ted 
to client race , age , and colposcopy diagno s i s . 
P i l o t  S tudy 
Prior to data c o l lec t ion , a p i l o t  s tudy was conduc t ed 
in February , 1 9 8 3  by the inve s t igator . The s tudy was 
conduc ted because of  the inves t igator ' s  interes t in oral 
contracep t ives and CIN as an area for fur ther research . 
The p i l o t  s tudy inc luded c�inical records of  cl ients who 
a t t ended a dona t ion and grant suppor t ed gyneco logy cl inic 
loca t ed in the same me tropoli tan area . The resu l t s  of the 
p i l o t  s tudy prompted fur ther inve s t igat ion to determine 
the re lat ionsh ip be tween CIN and oral contracep t ives . 
Inf ormation for  the p i l o t  s tudy was obta ined f rom a conve­
nience sample  of cyto logica l smear repor t s  taken from 86 
c l inical records of  c l i ents  who used s ix spec i f ic oral 
contracept ives . 
Resu l t s  of  the p i l o t  s tudy showed tha t f ive - s ix ths 
of the mi ld dysplas ia no t ed on cytological smear repor ts  
were a s socia t ed w i th a spec i f ic oral  contracept ive . I t  
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was a l s o  noted tha t s quamous me t aplasia and reac t ive changes  
t ended to be  more  frequently associa ted w i th lower es trogen 
dosages  o f  3 5  meg . or l e s s . The average age of  the p i l o t  
s tudy samp le  w a s  22 y ears . 
Da ta Co l lect ion Procedure 
This  s tudy was conduc ted be tween Oc tober , 1 9 8 3  and 
March , 19 8 4 .  Prior to da ta c o l lection,  permis s ion to review 
c l ient c l inical records was obtained from the s tudy 
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organ i zation ( Appendix D ) . The inve stigator met with 
appropriate nurs ing personne l to inf orm them of the study 
being conducted and to an swer any questions perta in ing to 
the study . The nur s ing supervi sor in the colposcopy c l inic 
was re spons ible for informing the sta f f  members about the 
study being conducted . 
The co lpo scopy c l inic nur s e  ut i l i zed part one of  the 
data colleci ion form on Monday between 9 : 00 a . m .  and 
1 1 : 00 a . m .  and Tuesday between 1 2 : 30 p . m .  and 3 : 30 p . m .  
A l l  c l ients attending the c l inic for the first time were 
interviewed by the nur se  and information concerning duration 
and type of oral contraceptive use was hand recorded on 
part one of the data c o l l ection form . The nur se  retained 
the data co l l ection form for the investigator to col lect 
each week from the c l inic . 
From the data col lection forms completed by the nur s e , 
the investigator determined c l inical record e l igibi l ity 
for inclus ion in the study . E l igibi l ity criteria inc luded 
the use  of one of the f ive spec i f ic oral contraceptive s 
with a minimum o f  s ix months usage . The investigator 
uti l i zed part two of the data c o l lection form to record 
age , race , and co lposcopic diagno s i s  from the cl ient ' s  
c l inical record . A total of  52 c l inical records of c l ients 
were identi f i ed ,  examined and inc luded in the study . 
CHAPTER FOUR 
Data Analy s i s  and Interpretation 
The purpo s e  of  thi s  study was to determine the re lation­
ship between spec i f ic oral contraceptives and cervica l 
intraepithe l i a l  neoplasia ( CIN ) � and to determine if  duration 
o f  u s e  and content o f  the oral contraceptive s were related 
to CIN . The des ign for thi s  study was a retrospective , 
corre lational des ign which al lowed for examination of  the 
as s oc iations between oral contraceptives and CIN . Data 
was c o l l ected f rom 52 c l inical records of c l i ents who 
attended a co lposcopy c linic dur ing a four-month period . 
The ana ly s is o f  data inc ludes three sections : s ection one 
inc ludes a description of study popu lation characteristics; 
s ecti on two inc ludes an ana ly s i s  of  spec i f ic oral contra ­
ceptives and CIN ; and s ection three includes a description 
of duration of oral contraceptive use and CIN . A discu s s ion 
of study results is  a l s o  inc luded in thi s  chapter . 
Data was anal y z ed by frequency and percent o f  oral 
contraceptive u s e , diagnoses , age and race . Data ana l y s i s  
a l s o  included Estimates o f  Re lative Risk ( ERR ) o f  spec i f ic 
diagno s es . Chi - s quare ana ly s i s  was uti l i z ed to determine 
the d i f ferences in frequency of spec i f ic diagnoses . Fi sher's 
exact one -ta i l  probability test was used to determine 
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proportional d i f f erences with a small sample s i z e  ( S iega l , 
1 95 6 ) .  Analy s i s  of  var iance (ANOVA) was used to evaluate 
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the s igni f icance of the a s s ociation of  oral contraceptive 
duration of use  with CIN as compared with oral contraceptive 
estrogen dosage and CIN . The level of s ign if icance for 
all statistical tests was placed at p < 0 . 05 with df  = 1 .  
Study Population Character i stics 
Table 1 
Age o f  Study Clients by Frequency and Percent , 
1 9 84 
Age ( years ) Frequency P ercent 
1 7 - 2 0  1 7  32 . 7  
2 1 - 2 5  1 9  36 . 5  
2 6 - 30 14 26 . 9  
3 1 - 33 2 3 . 8  
Total 52  1 00 . 0  
Mean age 2 3 . 3  years Age range 1 7 - 33 years 
Table 1 shows the age di str ibution of  the study popu­
lation . The age range was between 1 7  and 33 years of age 
with a mean age of 2 3 . 3  years . Approximate ly 69 percent 
( 6 9 . 0% )  of the sample population was younger than 26 years 
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o f  age  and 96  percent ( 96 . 0% )  were 30  years of age or younger . 
Inf ormation from the clinical records showed that only 3 . 8  
percent . ( 3 . 8% ) ,  or two clients, were over 30 y ears of  age . 
Figure 2 shows the age d i str ibution graphically . 
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Age o f  Study Population by Frequency and Percent 
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.O f  the total 52 clinical records of  clients examined , 
3 2  (61. 51 ) clients were black and 20 ( 38. 5%) of  the clients 
were wh�te . Although the univers ity hospital colposcopy 
clinic ref errals were from a wide range of private pnact�ces 
and public clinics , the larger number of black clienti may 
have been due to the univers ity hospital clinic being a 
state institution which s erves a large percentage of  the 
black population . 
Table 2 
Spec i f ic Oral Contraceptive U s e  of  Study Clients 
by Frequency and Percent , 1984 
Oral Contraceptive Number Percent 
Grou2 One ( 3 5  meg . of  estrogen or les s )  
Loestrin· 7 1 3. 5 
LoOvral 3 5. 8 
OrthoNovum 1/35  1 3  25. 0  
Subtotal 23  44. 3 
Grou2 Two ( 50 meg . of  estrogen ) 
OrthoNovum 1 /50 22 42. 3 
Ovral 7 1 3. 5  
Subtotal 29 55. 8 
TOTAL 52  100. 0 
Table 2 shows the di stribution o f  spec i f ic oral contra-
c eptive use  by  study clients . Client oral contraceptive 
use  ranged f rom three clients who used LoOvral to 22 clients 
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who used Or thoNovum 1 /50 ( ON 1/50 ) . The oral contra­
cept ive usage by client s  was divided into two subgroups 
based upon the es trogen content of the oral contracept ive . 
Thi s  grouping allowed for more comparable sample s i z e s  and 
compar ison o f  e s trogen dosage as sociat ed with CIN 
diagno s i s . Oral contracep t ives included in group one 
contained 35 meg . or les s  of e s trogen . Oral contracept ives 
in group two contained 50 meg . of es trogen . 
Forty- f our and three - t en ths ( 44 . 3% )  of  the s tudy 
clients  used oral contracept ives containing < 35 meg . of  
e s trogen and 55 . 8  percent ( 5 5 . 8% )  used oral contraceptives 
w i th 50 meg . of e s trogen . A to tal of  67 . 3  percent ( 67 . 3% )  
o f  the s tudy clients  used Or thoNovum produc t s . Of  thes e ,  
2 2  ( 4 2 . 3% )  used ON 1/50 and 1 3  ( 2 5 . 0% )  used ON 1/35 . 
Ovral produc t s  were used by 1 9 . 3  percent ( 1 9 . 3% )  and 
Loes trin was used by 1 3 . 5  percent ( 1 3 . 5% )  of the s tudy 
cli ents . The larger percentage of  ON produc t s  used by 
s tudy clients , repor tedly , could be due to the lower cos t 
o f  ON produc t s  a number of  y ears ago .  
Table 3 
Duration of Study Cl ient Oral Contraceptive 
U s e  by Frequency and Percent , 1 9 84 
Months Number Percent 
6 - 1 2  2 2  42 . 3  
1 3 - 3 6  1 2  2,3 . 1  
3 7 - 60 9 1 7 . 3  
6 1 - 9 6  9 1 7 . 3  
Subtotal > 1 2  30 57 . 7  
TOTAL 52 100 . 0  
Mean use 34 . 8  months 
U s age  range = 6 mos . - 96 mos . 
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Table 3 shows the duration of  o r a l  contraceptive u s e  by 
the study c l i ents . The mean duration of  use was 34 . 8  months 
and the range of usage wa s from s ix to 96 months . Oral 
c ontraceptives were used by 5 7 . 7  percent ( 5 7 . 7% )  of  the 
study c l i ents for  1 3  to 96 months , and 42 . 3  percent ( 42 . 3% )  
o f  the study c l i ents used oral contraceptives f o r  1 2  months 
or l e s s . S eventeen percent ( 1 7 . 0% )  of study c l ients used 
oral contraceptives for more than f ive years ( 60 months ) . 
For further ana ly s i s , duration of  oral contraceptive use was 
d ivided into two subgroups bas ed on spec i f ic time frames . 
One group inc luded 1 2  months or l e s s  of  oral contraceptive 
use , and the other group inc luded more than 12 months of  
oral contracept ive use . Dura t ion of  oral contracept ive 
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u s e  was divided into these  two groups because phy s iological 
balance o f  the oral contracept ive occur s dur ing the f i r s t  
1 2  months of  use . Conceivably , cervical t i s sue changes 
dur ing thi s  12 month per iod would be les s likely to be 
as sociated wi th oral contracept ive use  than changes tha t 
would occur af ter 1 2  months of  use . 
Table 4 
Colpo scopic Diagnoses  o f  Study Clients  
by Frequency and P ercent , 1984* 
D iagno s i s  
Mild dyspla s ia 
Moderate dy spla s i a  
Mild/modera t e  dyspla s i a  
' Subgroup to tal 
Severe dysplasia  
Carc inoma - in-s i tu ( CIS ) 
Severe dyspla s ia/CIS 
Subgroup total 
Condyloma as only diagno s i s  
Condyloma coexis t ing w i th CIN 
Condyloma 
Subgroup to tal 
TOTAL 
Number 
( N=52 ) 
3 1  
6 
3 7  
9 
3 
1 2  
3 
26 
2 9  
7 8  
Percent 
59 . 6  
1 1 . 5  
7 1 . 1  
1 7 . 3  
5 . 8  
23 . 1  
5 . 8  
50 . 0  
55 . 8  
1 00 . 0  
*To t al percent not 
dy spla s i a .  
1 0 0  due t o  coexi s t ing condyloma w i th 
Table 4 shows the di stribution of  colpo scopic 
diagnoses of  the study clients . There were 78 diagno ses 
for the 5 2  clients in the study because a client may have 
had both dyspla s ia and condyloma . Mild dyspla s ia was 
the mo st common diagno s i s  of  the study clients . 
Thirty - one ( 5 9 . 6% )  had m i ld dyspla s i a ,  29 ( 55 . 8% )  had 
condyloma, and three ( 5 . 8% )  had CIS . Levels of dysplas ia 
were divided into two subgroups : mild/moderate dyspla s ia 
and s evere dy splas ia/CIS . Mi ld/moderate dyspla s ia 
accounted for  7 1 . 1  percent ( 7 1 . 1% )  of  the diagno ses and 
s evere dy spla s ia/CIS accounted for 2 3 . 1  percent ( 23 . 1% )  
o f  the study cli ent diagnoses . Condyloma coexisting 
with dyspla s ia was found in 50 percent ( 50 . 0% )  of the 
study clients . Condyloma as a s ingle diagno s i s  accounted 
for 5 . 3  percent ( 5 . 3% )  o f  the study client diagnoses . 
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Table 5 
Oral Contracept ive U s age and Associated Diagno s i s  by Frequency , Percent and ERR , 1984  
DIAGNOS I S  AND ERR 
Mild/moderat e  dy spla s ia S evere dysplas ia/CIS Condy loma 
Oral Mild/ S evere/ 
Contra- Mild Mod . Mod . S evere CIS  C I S  Candy-
c ept ive ERR ERR lorna 
F p F p F p F p F p 
Loe s t in 3 42 . 9  2 2 8 . 6  1 . 02 1 1 4 . 3  0 0 0 . 5 2 6 8 5 . 7  
( N=7 ) 
LoOvral 2 66 . 7  0 0 0 . 80 0 0 1 3 3 . 3  1 .  7 3  0 0 
( N= 3 )  
>'<ON 1/35 1 1  8 4 . 6  2 1 5 . 4  1 9 5 . 0  0 0 0 0 0 6 46 . 2  
( N=1 3 )  
ON 1/50 1 3  59 . 1  1 4 . 6 0 . 5 3 6 2 7 . 3  1 4 . 5  3 . 2 7  1 4  63 . 6  
( N= 2 2 )  
>'<Ovral  2 2 8 . 6  1 1 4 . 3  0 . 24 2 2 8 . 6  1 1 4 . 3  3 . 00 3 42 . 9  
( N=7 ) 
TOTAL 3 1  59 . 6  6 1 1 . 5  9 1 7 . 3  3 5 . 8  2 9  5 5 . 8  
*Fi sher ' s  Exac t One -Tail Tes t :  
incidence of dysplas ia p = 0 . 02 s ignif icant a t  the p < 0 . 05 leve l 
inc idence of  condy loma p = 0 . 49 no t s igni f icant a t  the p < 0 . 05 level 
C andy -
lorna 
ERR 
5 . 74 
0 
0 . 60 
1 .  7 5  
0 . 50 
Total 
F p 
1 2  15 . 4  
3 3 . 8  
1 9  24 . 4  
3 5  44 . 9  
9 1 1 . 5  
7 8  100 . 0  
V1 
00 
Table 5 shows the oral contraceptives and assoc iated 
GIN diagno s e s  for  the study clients . Percentages  of GIN 
diagnoses were determined from the number of  diagnoses  
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for each spec i f ic oral contraceptive used by the study 
clients . Loestr in users had the highest percent of  condy­
loma . Of the seven Loestrin users , 8 5 . 7  percent ( 8 5 . 7% )  
had condyloma . The 2 2  O N  1 /50 users had the s econd highest 
percent of  condyloma . Of the ON 1 /50 users , 14 (63 . 6% )  
had condyloma . Condyloma wa s diagnos ed for 46 . 2  percent 
( 46 . 2% )  o f  the ON 1/35  user s . All o f  the ON 1 /3 5  user s  
als o  had e ither mild o r  moderate dyspla s i a .  Mild dysplasia  
was  d iagno s ed for 84 . 6  percent ( 84 . 6% )  o f  the ON  1/35 users 
and moderate dyspla s i a  was diagno s ed for 15 . 4  percent 
( 15 . 4% )  o f  the ON 1 / 3 5  user s . There were no diagnoses  of  
s evere dy splas ia/CIS for ON 1/35  users . 
The percentage of  s evere dysplasia and CIS  was highest 
for users of oral contraceptives containing 50 meg . of 
estrogen .  Severe dy splas ia was diagnosed for 2 7 . 3  percent 
( 2 7 . 3% )  o f  the ON 1 /50 users and 28 . 6  percent ( 2 8 . 6%)  of  
the Ovral user s . 
Table 5 also  shows the Estimate s of Relative Risk ( ERR ) 
for  the spec i f ic diagnoses . ERR was calculated for the 
combined number o f  mild and moderate dy splas i a  diagnoses , 
and for the combined number of  severe dysplas ia and CIS  
diagnoses . 
The ERR ( 5 . 74 )  of  condyloma was nearly s i x - fold for 
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Loestrin users as  compared with an ERR of  z ero ( 0 . 0 )  for 
LoOvral user s . The ERR o f  condyloma was 1 . 7 5 for ON 1/50 
user s . For a l l  other oral contraceptives us ed by the study 
clients , the ERR of condy loma was le s s  than one . 
The ERR o f  s evere dysplas ia/CIS was at least three - f old 
for both oral contraceptives containing 50 meg . of estrogen . 
The ERR o f  s evere dysplas ia/CIS was 3 . 2 7  for ON 1 /50 users 
and 3 . 0  for Ovral user s . ON 1/35 users had an ERR of  
mild/moderate dysplasia  of  195 . 0  and no  risk for severe 
dy splas ia/CI S . 
Fi sher's exact one -tail test was used to compare the 
f requencies  o f  dyspla s i a  and condyloma for ON 1/35  and 
Ovral user s . These  two oral contraceptives were used to 
compare 35 meg . and 50 meg . dosages of the estrogen ethinyl 
estradiol . The d i f f erence in inc idence of dy splasia 
between the ON 1/35 and the Ovral users was s ignif icant 
with Fi sher's exact one-ta i l  test at the p < 0 . 05  level . 
The incidence o f  condyloma was not s ignif icantly d i f ferent 
between ON 1/35  and Ovral users . Figure 3 shows the 
percentage o f  dyspla s ia for ON 1/35 and Ovral users by 
study clients in graphic f orm . 
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Table 6 
Levels of  Dy splas ia Associated w i th Dosages o f  Es trogen 
by Frequency , Percen t and ERR , 1 9 8 4  
O r a l  Con tracept ive Mi ld/Moderate  
Dosage Dy splas i a  
F p ERR 
,., < 35 meg . 20 90 . 9  4 .  7 1  
-·· 50 meg . 1 7  63 . 0  0 . 2 1  
TOTAL 3 7  7 5 . 5  
*Fi sher ' s  exac t one - tail  tes t : p = . 0 24 
S ign i f ican t at p < 0 . 05 leve l 
ANOVA F value = 5 . 93 .  pr > F = 0 . 0 1 8 8  
S evere Dy splas ia/ 
CIS  
F p ERR 
2 9 . 0 0 . 1 8 
10  3 7 . 0  5 . 5 2 
1 2  2 4 . 5 
Sign i f ican t p < 0 . 05 level ( R  s quare = 0 . 1 2 )  
F 
2 2  
2 7  
49 
To tal 
p 
44 . 9  
55 . 1  
100 . 0  
"' 
N 
63 
Table 6 shows dy spla s ia by frequency , percent �nd ERR 
associated with the two dosages of  estrogen used by study 
cli ents . The percen t of mild/moderate dyspla s ia for users 
o f  oral contraceptives with � 3 S  meg . of  estrogen was 90 . 9  
percent ( 90 . 9% )  with an ERR o f  4 . 7 1 .  The percent o f  s evere 
dy splasia/CIS f o r  this  oral contraceptive group was 9 . 0 
percent ( 9 . 0% )  with an ERR of  0 . 1 8 .  U s er s  o f  SO meg . 
estrogen oral contraceptives had a 3 7 . 0  percent inc idence 
( 3 7 . 0% ) . o f  s evere dy splas ia/CIS and an ERR of S . S 2 .  The 
inc idence o f  mild/moderate dysplasia  for SO meg . estrogen 
oral contraceptive users was 63 . 0  percent ( 63 . 0% )  with an 
ERR of 0 . 2 1 .  
The d i f f erence between the two groups of  oral contra­
ceptive e strogen do sages and levels of dyspla s ia was 
stati stically s igni f icant with Fisher ' s  ex�ct one -tail 
test . ANOVA showed that e strogen do sage and level of 
dysplasia was s igni f icant at the p < O . OS level of 
s ignif icanc e .  Figure 4 shows the percentage o f  dysplas ia 
d iagnoses  f o r  users o f  � 3S  meg . estrogen and SO meg . 
estrogen oral contraceptive s .  
100 
64 
90 . 9  
63 . 0  
3 7 . 0  
9 . 0  I 
Mild/mod . S evere/CIS 
Dysplasia  
Mild/mod . S evere/CIS 
< 3S meg . es trogen SO meg . es trogen 
Figure 4 
Percentage of  Dysplasia  Diagno ses for U s ers of  
� 3S  meg . Es trogen and S O  meg . E s t rogen 
Oral Contracept ives 
Table  7 
Condy loma Associa ted w i th Oral Con tracep t ive 
Es trogen Dosages by Frequency , Percen t and 
ERR , 1 9 84 
Oral 
Con tracept ive Condyloma Es trogen 
Do sage F p ERR 
�': < 3 S  meg . 1 2  S 2 . 2  0 .  7 7  -( N= 2 3 )  
"'k SO me� . 1 7  S 8 . 6  1 . 30 
( N=29 
TOTAL 2 9  S S . 8  
( N= S 2 ) 
*Chi - s quare va lue = 0 . 2 16 Probabi l i ty 0 . 64 
N o t  s ignif icant a t  the p < O . OS level 
6S 
Table 7 shows the f requency , percent and ERR of  condyloma 
a s s ociated wi th dosages of  es trogen used by s tudy c l i en t s . 
The SO meg . es trogen oral con tracept ive users had S 8 . 6  
percent incidence ( S 8 . 6%)  o f  condy loma and an ERR o f  1 . 30 .  
U sers o f  oral con tracept ives con taining � 3 S  meg . of es trogen 
had a S2 . 2  percen t inc idence ( S 2 . 2% )  of  condy loma and an 
ERR of 0 . 7 7 .  
Oral 
Table 8 
Compar i·son o f  Norge s trel- Containing and O ther Con tracept ives 
As socia ted w i th Dysplasia  Diagno s e s  by Frequency , Percent 
and ERR , 1984  
M ild/Modera te Severe/CIS 
Contracept ive Dy splas i a  Dy splasia  Total 
F p EER F p EER F p 
>'<Norges trel 5 5 5. 6  0. 3 1  4 44. 4  3. 20 9 1 8. 3 7 
oc 
( N=9 ) 
>'<O ther OC 3 2  80. 0 3. 20 8 20. 0  -0. 3 1  40 8 1. 63 
( N=40 ) 
TOTAL 3 7  7 5. 5  1 2  24. 5 49 100. 0 
*Fi sher ' s  exact one- tail  tes t p = 0. 1 342 
Not  signi f i cant a t  the p < 0. 05 leve l 
(j\ 
(j\ 
67 
Table 8 shows the dy spla s ia diagno ses  by frequency , 
percent and ERR of  u s er s  of  oral contraceptives con­
tain ing norgestrel ( Ovral  and LoOvral ) and other contra­
ceptives us ed by study c l ients . Thi s  compar is on was done 
in order to determine if  there was a d i f f erence in CIN 
a s s oc iated with norgestrel-conta in ing oral contraceptives .  
O f  the norgestrel-contain ing oral contraceptive users , 
44 . 4  percent ( 44 . 4% )  had s evere dysplas ia/CIS with an 
ERR o f  3 . 20 ,  and 55 . 6  percent ( 5 5 . 6% )  had mild/moderate 
dysplas i a  with an �RR of 0 . 3 1 .  The other oral contra­
ceptive users  had a 20 . 0  percent ( 20 . 0% )  incidence of  
s evere dysplas ia/CIS with an  ERR of  0 . 31 and an  80 percent 
( 80 . 0% )  incidence of mild/moderate dysplas i a  with an ERR 
of 3 . 20 .  Fi sher ' s  exact one-tail test did not show a 
s ignif icant d i f ference between thes e  two oral ·contra­
ceptive u s er groups . 
Table 9 
Compari son o f  Norges trel-Containing and Other 
Oral Con tracept ive U s er s  As socia ted w i th 
Condyloma by Frequency , Percent and ERR , 
1 9 84 
Oral 
Contracept ive 
�':Norges trel 
( N=9 )  
*O ther Oral 
Contracept ives 
( N=40 ) . 
TOTAL 
( N=5 2 )  
F 
3 
26 
2 9  
Condyloma 
P ERR 
3 3 . 3  0 . 2 7  
65 . 0  3 . 70 
5 5 . 8  
*Fi sher ' s  exac t one - tail t e s t  p = 0 . 045 
S igni f icant at the p < 0 . 0 5 level 
Table 9 shows the frequency , percent and ERR of  
condyloma diagnoses  as sociated wi th users  of  
68 
norges trel-containing oral contracep t ives as  compared w i th 
condyloma diagno s i s  associa ted w i th o ther oral contra-
c ep t ive s . Norges trel-containing oral contraceptive use  
was  a s sociated w i th a 3 3 . 3  percent ( 33 . 3% )  inc idence of 
condyloma and an ERR of  0 . 2 7 .  The o ther oral contracept ives 
u s ed by s tudy clien t s  were associa ted w i th 65 . 0  percent 
( 65 . 0% )  incidence of  condyloma and an ERR of 3 . 7 .  Results  
were  s igni f icant when Fi sher ' s  exac t one - tail test  was 
applied t o  this da t a .  
Table 10 
Dy spla s ia As soc iated with Duration of Oral 
Contraceptive u s e  by Frequency, Percent 
and ERR , 1984  
Duration of  Oral 
Contraceptive U s e  Mild/Moderate Severe Dy splas ia/ 
( in months ) Dy spla s ia C IS 
F p F p 
-·- < 1 2  1 5  7 1 . 4  6 2 8 . 6  
o': > 1 2  2 2  7 8 . 6  6 2 1 . 4  
TOTAL 3 7  7 5 . 5  1 2  2 4 . 5  
*Chi- square 0 . 332 ; p = 0 . 56 .  
Not s ign i f icant at the p < 0 . 05 . level 
ANOVA F value = . 0 . $2 ; . p:�; , ) ,Q .. ,3693 ; . ( R  square , = 0 . 1 2 )  
Not s ignif icant at p < 0 . 05 leve l 
ERR 
1 . 47  
0 . 68 
F 
2 1  
2 8  
49 
Total 
p 
42 . 9  
5 7 . 1  
100 . 0  
0"\ 
'-'> 
Table 10 shows dyspla s ia associated. with duration of  
client oral contraceptive use by  frequency , percent and 
ERR of s evere dysplas i a .  The percent of mild/moderate 
dy splas ia was slightly higher among users of oral contra ­
ceptives for more than 1 2  months as  compared with users 
for  12 months or les s . Of the oral contraceptive users 
for more than 12 months , 7 8 . 6  percent ( 7 8 . 6% )  had 
mild/moderate dyspla s ia . U s ers o f  oral contraceptives 
for  1 2  months or les s  had a 7 1 . 4  percent ( 7 1 . 4% )  inc idence 
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o f  mi ld/moderate dysplas ia . The percent o f  severe dyaplas ia/ 
C I S  was s l ightly higher for users with 12 months or les s  
of  oral contraceptive us e .  U s er s  of  oral contraceptives 
for more than 1 2  months had a 2 1 . 4  percent inc idence 
( 2 1 . 4% )  of s evere dysplas ia/CIS with an ERR of 0 . 68, 
as compared with 2 8 . 6  percent ( 2 8 . 6% )  and ERR of 1 . 4 7 for 
users of  oral contraceptives less than 1 2  months . 
Chi-square and ANOVA ana l y s i s  did not show s ignif icance 
when applied to thi s  data . 
Tab le 1 1  
Dur a t ion o f  Oral Con tracep t ive U s e  As socia ted w i th 
Condy loma by Frequency, Percen t and ERR , 1984  
Dura t ion of 
Ora l Con tracept ive 
U s e  
* < 1 2  months 
( N= 2 2 )  
* > 1 2  mon ths 
( N=30 ) 
TOTAL 
( N=5 2 )  
*Chi - s quare va lue 1 . 645 
probabi l i t y  = 0 . 1997  
Condyloma 
F p 
10 45 . 5  
19 63 . 3  
29 5 5 . 8  
n o t  sign i f ican t a t  p < 0 . 05 leve l 
ERR 
0 . 48  
2 . 07  
71  
Table 11  shows the duration of  oral  con tracep tive use 
as socia ted w i th condy loma by frequency, percen t and ERR . 
A higher percen t o f  condy loma was no t ed for cl ien t s  who 
u s ed oral contracept ives for more than 1 2  months as compared 
wi th users for 12 mon ths or l e s s . Oral con tracept ive users 
o f  more than 12 months had a condy loma incidence of  63 . 3  
percen t ( 63 . 3% )  w i th an ERR of  2 . 0 7 .  U s er s  of  oral con tra-
c ep t ives for 12 mon ths or less had a condyloma incidence 
of  45 . 5  percen t ( 45 . 5% )  wi th an ERR of  0 . 4 7 .  Condy loma 
inc idence was calculated as a percen tage of a l l  o ther CIN 
diagnos e s  for each durat ion of oral con t racept ive us e .  
Table 1 2  
Dura t ion o f  Oral Contracep t ive U s e  As sociated w i th Es trogen Dosage 
and Dysplasia by Frequency and Percen t ,  1984  
Durat ion o f  Oral  Contrace2t ive U s e  
< 1 2  months > 12 mon ths 
i 35 meg . 50 meg . i 3 5  meg . 50 meg . 
Diagnosis  Es trogen Es trogen E s trogen Es trogen 
F p F p F p F p 
M i ld/ 10  90 . 9  5 50 . 0  1 0  90 . 9  1 2  70 . 6  
Moderate 
Dysplasia 
Severe 1 9 . 0  5 50 . 0  1 9 . 0 5 29 . 4  
Dy splas ia/ 
CIS 
TOTAL 1 1  100 . 0  10  100 . 0  1 1  100 . 0  1 7  100 . 0  
-...J 
N 
7 3  
Tabl e 1 2  shows the durat ion of  oral contracep t ive use 
as sociated w i th es trogen dosage and dysplasia by frequency 
and percen t . Of the oral contracept ive users for 1 2  months 
or l es s , users of 50 meg . es trogen oral contracept ives had 
the highes t incidence of severe dysplas ia/CIS as compared 
w i th � 3 5  meg . es trogen oral contracept ive users . F i f ty 
percent ( 50 . 0% )  of  50 meg . es trogen oral contracep t ive 
users had s evere dysplas ia/CIS d iagnoses  as compared w i th 
nine percent ( 9 . 0% )  o f  the � 3 5  meg . es trogen oral contra­
cep t ive users . The inc idence o f  mi ld/modera te dysplas ia 
for oral contracept ive users of  l e s s  than 1 2  months was 
90 . 9  percent ( 90 . 9% )  for � 35 meg . es trogen oral contra­
ceptive users as compared w i th 50 percent ( 50 . 0%)  for 
50 meg . es trogen oral contracep t ive user s . 
O f  the oral contracept ive users for more than 1 2  
months , users  of  5 0  meg . es trogen oral contraceptives also 
had the highes t  incidence of  s evere dy splas ia/CIS as  com­
pared wi th < 3 5  meg . es trogen oral contracept ive users . 
Users  of  50 meg . es trogen oral contracep t ives had a 2 9 . 4  
percent ( 2 9 . 4% )  inc idence o f  s evere dysplas ia/CIS as com­
pared w i th a nine percent ( 9 . 0% )  inc idence for � 35 meg . 
e s trogen oral contracept ive users . The incidence o f  
mild/moderate dysplasia f o r  oral contracep t ive users of  
more  than 1 2  months was  90 . 9  percent ( 90 . 9% )  for � 35 meg . 
es trogen oral contracept ive users as compar ed wi th 70 . 6  
percent ( 70 . 6% )  for 50 meg . es trogen oral contracept ive 
users . 
Chi - square analy s i s  could not  be used wi th this  data 
because  cell coun t s  were le s s  than f ive for 20 percent of 
the cells . 
Table 13  
Condyloma Diagnoses  Associated w i th Dura t ion of  
Oral Contracept ive U s e  and Es trogen Dosage 
by Frequency and Percent , 1984  
Dura t ion 
'" < 12 mo . 
Subto tal 
''< > 1 2  mo . 
Subto tal 
TOTAL 
Es trogen 
Dosage 
< 35 me� . 
( N=1 1 )  
50 me� . 
( N= 1 1 )  
( N= 2 2 )  
< 35 me� . 
( N= 1 2 ) 
50 me� . 
( N=1 8 )  
( N=30 ) 
( N=5 2 )  
F 
5 
5 
10  
7 
1 2  
1 9  
2 9  
*Chi - s quare value 1 . 8 7 6  p < 0 . 5 9 
N o t  signif ican t a t  the p < 0 . 05 leve l 
p 
45 . 5  
50 . 0  
45 . 5  
63 . 6  
7 0 . 6  
6 7 . 9  
5 5 . 8  
74  
Table 1 3  shows the condyloma diagno ses  associa ted w i th 
dura t ion o f  oral con tracept ive use and oral con tracept ive 
e s trogen dosage . U s ers of  i 3 5  meg . e s t rogen oral 
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contracep t ive s for 1 2  months or less  had frequencies o f  
condyloma equa l to the frequencies of  5 0  meg . es trogen 
oral  contracept ive user s . C l i ents  us ing 50 meg . oral 
contracept ive s for more than 1 2  months had a 70 . 6  percent 
( 70 . 6% )  inc idence of  condy loma as compared w i th a 63 . 6  
percent ( 63 . 6% )  incidence for users o f  < 3 5  meg . es trogen 
oral  contracep t ives . Chi - s quare analysis  was not 
s ignif icant for this data . 
Da ta Interpretat ion 
The maj or i ty · o f  the s tudy cl ients  were black and younger 
than 26 y ears of  age . ON 1 /50 was the mos t fr equent ly used 
oral contracept ive and LoOvra l  the lea s t  frequently used.  
There were f ewer users of  < 35 meg . es trogen oral contra­
cept ive s than users of 50 meg . oral contracep t ives . 
Mi ld/moderate dy splasia was the mo s t  f requent CIN diagno s i s . 
Carc inoma - in- s i tu was the lea s t  frequent CIN diagno s i s  for 
oral contracept ive users . Condy loma was the second mos t 
frequent CIN diagno s is for oral contracept ive users . 
More of  the s tudy c l ients used oral contracept ives 
f o r  more than 12 months than users for 12 months or less . 
ON 1/35  users had the highe s t  frequency of  mild dysplasia 
and Ovra l  users had the lowe s t  frequency o f  m i ld dysplas ia . 
U s e r s  of  Loes trin had the highes t  frequency o f  moderate 
dysplas ia . ON 1/35 users had the highes t  ERR of  m i ld/ 
modera te dy spla s ia . Ovral  users had the highes t  percentage 
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o f  s evere dysplas i a .  LoOvral and O N  1 / 3 5  had no sev�re 
dysplasia diagno ses . Al though LoOvral  users had the 
highe s t  percen tage of  CIS , ON 1 /50 and Ovral  had the highe s t  
ERR o f  severe dysplas ia/CIS . Loe s trin users had the highes t  
percen tage and ERR o f  condy l oma and LoOvral had the lowe s t  
percentage and ERR of  condy loma . 
U s ers of  50 meg . es trogen oral contracept ives had a 
higher percen tage and ERR o f  s evere dysplas ia/CIS than 
u s er s  of � 35 meg .  es trogen oral con tracep t ives . U sers 
of  � 35 meg . es trogen oral con traceptive s had a higher 
percen tage and ERR of mi ld/modera te dyspla s ia than users 
of < 50 meg . es trogen oral con traceptives . U s ers of  50 
meg . es trogen oral con tracep t ives a l s o  had a higher 
percen tage and ERR of condy loma than users of � 35 meg . 
es trogen oral con tracept ives . Users of norges trel-con taining 
oral con tracept ive s had a higher percen tage and ERR of 
s evere dysplas ia/CIS than the o ther oral con tracep t ive 
users in the s tudy . U s ers of norges trel -con tain ing oral 
con tracept ives also had a lower percen tage and ERR of 
mi ld/modera t e  dysplasia and condyloma than the o ther oral 
con tracept ive users in the s tudy . 
U sers of  oral con tracept ives for 1 2  mon ths or l e s s  
had a somewha t higher percen tage and ERR of  severe 
dysplas ia/CIS as compared wi th oral contracept ive users 
of  more than 12 months . The percen tage of  mi ld/moderate 
dy splas ia was highes t for users of  oral con tracept ives for 
more than 12 months . The percen tage of  condyloma was 
highes t  for users of  oral con tracept ives for les s  than 1 2  
mon ths . 
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U s ers o f  50 meg . es trogen oral contracept ives had the 
highe s t  percen tage of s evere dysplas ia/CIS for oral con tra­
cept ive users of  both 12 mon ths or les s  and more than 12 
months . U s ers of  � 35 meg . es trogen oral con tracept ive s 
had the highes t  percen tage of  mild/moderate dyspla s ia for 
users bo th 12 months or les s  and more than 1 2  mon ths users . 
The f requency of  condyloma was highes t for client s  with 
more than 1 2  months usage of 50 meg . es trogen oral contra­
cept ives and lowe s t  for clien ts  w i th 1 2  months or les s  
usage o f  5 0  meg . es trogen oral con tracept ives . Frequency 
of condyloma was lowes t  for bo th es trogen dosages of oral 
con tracept ives w i th 1 2  mon ths or les s  o f  use and highes t 
for  both es trogen dosages of oral con tracept ives w i th more 
than 12 months of  us e .  
There  were s ignif ican t d i f f erences for the inc idence 
of dyspla s ia be tween � 35 meg . es trogen and 50 meg . es trogen 
oral contracept ive users and be tween ON 1/35 and Ovral user s . 
D i f f erences were also  found in the inc idence of  condyloma 
be tween norge s t rel-contain ing and o ther oral contracept ive 
user s . 
CHAPTER FIVE 
Summary , Conclus ions , Implica t ions 
and Recommenda t ions 
Thi s  s tudy was conduc ted to determine the rela tionship 
be tween s pec i f i c  oral contracept ives and cervical intra­
epi thelial neoplasia  ( CIN ) , and to de termine if  the durat ion 
of use and the con ten t of  oral con tracept ives were rela ted 
to CIN . The inves t igator ' s  mo t ivat ion for this s tudy was 
the poten t ial increa sed CIN r i s k  tha t may be associa ted 
wi th the use of spec i f ic oral con tracep t ives . The inve s t i ­
gator was als o  concerned wi th the need for fur ther inve s t i -
g a t i on of  the as soc ia t ion be tween condyloma and oral con tra-
c ep t ive us e .  Differences be tween CIN levels as sociated 
w i th spec i f ic oral contracept ive use  by the s tudy popula tion 
provided ins ight in to this  problem . 
Epidemiological concep ts  for the inve s t igat ion of  
d i s ea s e ,  and Chrisman and Fowler ' s  Sy s tems - in-Change model 
( 1 9 8 0 )  were u t ilized for inve s t igat ion of the rela t ionship 
be tween oral con tracept ives and CIN . Epidemiological con-
cep t s  and the Sy s tems - in -Change model provided a sys tematic 
approach to inves tigate the in teract ion of  hos t ,  agen t 
and environmen tal factors which apply to CIN and associa ted 
oral contracept ive us e .  
This  s tudy analy z ed 5 2  clin �cal records o f  clien t s  
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who a t t ended co lposcopy clinic over a four-month period . 
A two - s tage inve s t igator-des igned data col lect ion form was 
u t i l i zed to obtain s elected demographic data and information 
per taining to oral con tracept ive use and GIN diagnoses . 
Par t one of  the data collect ion form was comple ted by the 
co lpos copy .c l inic nur se  who col lec ted informa t ion pertaining 
t o  type and durat ion of  oral contracep tive use by c l ien t s . 
Par t two was completed by the inve s t igator who obtained 
demographic informa t ion and co lpo scopy diagnoses from c l ient 
c l inical records . Ana lysis  o f  data was conduc ted based 
on the 52 c l ien t  c l inica l records . 
The mean age of the s tudy populat ion was 23 . 3  years 
and mo s t  o f  the cl i en t s  inc luded in the s tudy were black . 
The mo s t  frequen t con tracep t ive used by c l ien t s  was ON 1/50 
and the mean durat ion of use varied from s i x  mon ths to 96 
mon ths . The mo s t  fr equen t GIN diagnos is  was m i ld dysplasia 
f o l l owed by condyloma . Fi sher ' s  exact one- tail  tes t ,  
Chi-square ,  ANOVA and E s t ima t e s  o f  Relative Risk ( ERR ) were 
u t i l i z ed to ana lyze  data . 
Di scus s i on and Conc lus ions 
Maj or f indings in this  s tudy indicated tha t 50 meg . 
es trogen oral con tracept ive use was assoc ia ted w i th a grea t er 
r i sk o f  s evere dysplasia/CIS than r i sk associa ted wi th 
< 35 meg . e s t rogen oral contracep t ive us e .  Norge s trel-
con taining oral contracept ive users  had a greater r i sk of  
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severe dysplas ia/CIS than users of  other oral contraceptives .  
The percentage of  condyloma ass ociated with 
norgestrel-c0ntaining oral contraceptive use was somewhat 
lower than for other oral contraceptive users in the study . 
The maj or ity o f  condyloma diagnoses  coexisted with dysplas ia . 
The duration o f  oral contraceptive use was not associated 
with the level of CIN in this  study. 
F i sher's exact one-tail test and ANOVA showed a 
stati stically s ignif icant d i f ference in the incidence of  
dy spla s ia between � 35 meg . estrogen and 50 meg . estrogen 
oral contraceptive user s . Fi sher's exact one-tail test 
als o showed statistically s ign i f icant d i f f erences in the 
inc idence o f  dysplas ia between ON 1/35 users and Ovral user s . 
Dif f erences  in the inc idence of  condyldma between 
norgestrel-containing oral contraceptives and other oral 
contraceptive users was also  statistica l ly s ignif icant with 
Fi sher ' s  exact one-tail test . 
The investigator conc luded that there were dif ferences 
between s pec i f ic oral contraceptives and the associated 
incidence of CIN . The investigator also  concluded that 
thes e  di f f erences were not a s s ociated with duration of  us e .  
The clients in this  study were younger than study 
participants in previous res earch . However , f indings 
f rom this  study regarding the age range for highest 
prevalence of CIN support other study f indings·. Age may 
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b e  a fac tor in the developmen t of CIN because of . the vulner­
abi l i ty t o  carcinogenic inf luences assoc ia ted with a high 
degree of c e l lu lar ac t ivity in younger popula tions . Findings 
f rom this s tudy also  suppor t previous research findings 
of a higher incidence of  CIN among the bl ack populat ion . 
The inc idence of  condy loma was somewha t higher in this 
s tudy than noted in previous research . This  could be due 
t o  an increase in detec t ion of  condy loma in the general 
populat ion. The increased f inding of  condy loma among oral 
con tracep t ive users could be due to the increas ed viabi l i ty 
o f  condyloma on vulnerable cervica l epi the lium . 
The as sociat ion of  50 meg . es trogen oral con tracept ive 
use  w i th a greater r i sk of severe dysplas ia/CIS was also  
s uppor t ed by previous res earch . Thi s  f inding may be due 
to an es trogenic s t imula tion of cel lu lar maturat ion which 
may increa s e  the vulnerab i l i t y  of  the oral con tracept ive 
u s er to c arcinogenic inf luences . 
The presen t s t udy f inding of  a low incidence of  
condy loma a s s ociated w i th norge s trel -con taining oral con tra­
cept ive use was not no ted in previous research . The reason 
for  the low inc idence is  unc lear . I t  is  pos s ible tha t this  
oral con tracept ive has a pro tec t ive effec t , or i t  could 
be as soc i a t ed wi th o ther confounding factor s ,  such as number 
of s exual  partners . 
A l though the incidence of  condy loma was s l ight ly 
h igher among longer durat ion oral con tracept ive users , thi s  
8 2  
study did not support previous res earch which indicated 
that duration of oral contraceptive use  was ass ociated with 
CIN . 
The f ina l resu lts of  data analys is  in this  study 
s upported the hypothe s i s  that use  of norgestrel-containing 
oral  contraceptives was as sociated with a greater frequency 
of s ever e CIN changes than u s �  of other oral contraceptive 
products . 
The study results did not support the hypothe s i s  that 
longer duration of  oral contraceptive use  was as soc iated 
with a greater f requency of severe CIN changes . 
Impl ications 
There were several important f indings in this  study . 
One important finding was the as sociation between SO meg . 
e strogen oral contraceptive use  and the increased risk  of  
s evere dysplas ia/CIS . Another important study f inding was 
the increased s evere dysplas ia/CIS risk  and the decreased. 
condy loma r i s k  ass ociated with norgestr e l -conta ining oral 
contraceptive us e .  Lack o f  association between duration 
of oral contraceptive use and CIN was also  an important 
study f inding . 
Thi s  study emphas i z ed the importance and recognition 
of epidemio logical concepts in the development of  diseas e .  
I n  uti l i z ing epidemio logical concepts it i s  important to
· 
r ecogniz e  that patterns of disease depend upon the inter-
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act ion o f  agent , hos t and environmen t which may b e  affected 
by t ime . Based on the f indings of this  s t udy , specific 
oral con t racept ive use  by cl ien t s  may affec t  the in t erna l 
phy s io logical and immunological environmen t of the clien t . 
Durat ion ( t ime ) of oral con tracept ive use did not  have a 
s ign i f ican t ef fect on di sease outcome in this  s tudy . Based 
on pres en t  s tudy f indings , the c l inical s tage of CIN and 
po ten t ia l  r i s k  tha t the cl ien t  may progress  to ac tual 
cervical cancer may be mo s t  af fec ted by the es trogen dosage 
of the oral con tracept ive . 
C IN changes may be a func tion of mul t iple cl ien t  sys tems . 
D i s equi l ibr ium may occur as the c l ient move s from one deve lop­
men tal  s tage to ano ther , such as f rom adolescence to young 
adul thood . The disequi l ibr ium associated w i th the ef fec ts  
o f  the oral con tracep t ive agen t may promo te vulnerab i l i ty 
f o r  s tress  on the c l ient sys tem . The inab i l i ty of the c l ien t  
t o  compensate  f o r  this s tress  may lead t o  the deve lopment 
o f  d i s eas e .  
The Sy s t ems - in - Change model ( 1 980 )  i s  an impor tant 
and nec e s s ary approach to as ses smen t of the mul t iple cl ien t 
s y s tems as socia ted w i th the deve lopment of disea s e .  
U t i l i z ing the sys tems approach i n  a s s e s s ing the c l i en t ,  
the nur s e  prac t i t ioner can intervene in the progression 
of CIN by eva luat ing biologica l ,  social and per s onal 
s y s t ems of the clien t . The nurse prac t i t ioner needs to 
as s e s s  for s igns of dys func t ion inc lud ing envir�nmen tal 
variables which may influence the functi oning of  the se 
sys t ems. Cl ient asses sment is  based on the ac tual or 
po t ential  dys func t ion of  one or more of  the client sys tems 
and the deve lopment of CIN . 
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B ased on  a s s e s sment of the c l ient who is  us ing oral 
contracept ives , the nur s e  prac t i t ioner can intervene to 
reduce c l i ent risk of CIN . The prac t i t ioner ' s  p lan of care 
shou ld inc lude provi s ion of  appropr iate c l ient teaching 
and couns e l ing regarding the deve lopment of CIN , and pre� 
scr ibing the low�s t po s s ible es trogen dosage oral contra­
ceptive tha t wi l l  be effec t ive for the cl ient . 
U t i l i z ing the Sy s tems - in- Change model ( 1 9 80 )  and 
epidemio logical concep ts  for a s s e s sment and intervent ion 
in the deve lopment of disease, the nur se  prac t i t ioner can 
promo t e  the optima l we l l-be ing of c l i ents  who are us ing 
oral contracep t ive s . 
Recommenda t i ons for Fur ther Res earch 
Several  recommenda tions for further res earch are 
s ugges t ed : 
1 .  Repl icat ion of  this  s tudy w i th a larger and more 
d ivers e  populat ion to determine if  d i f ferences  in CIN 
diagnoses  and associated oral contracept ive use are the 
s ame as tho s e  found in this s tudy . 
2 .  Fur ther inve s t iga t ion of  demographic variables 
a s s oc ia ted wi th CIN such as, number of  s exual partners and 
age of  f i r s t  sexual intercours e .  
3 .  Fur ther res earch tha t u t ilizes  a demographically 
matched control group in order to clarify the poss ible 
a s s ociat ion be tween CIN and oral contracept ive use .  
4 .  Fur ther inve s t iga tion o f  the associat ion be tween 
CIN and the e s t rogen and proges togen component s  of oral 
contracep t ives . 
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5 .  Fur ther inve s t igat ion of  the rela t ionship be tween 
oral contracept ive use and the development of  condyloma . 
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F ive Ora l Contracep t ives by Brand Name and Progestogen 
and Es trogen Composi t ion ( Dong and Eof f ,  1 9 7 8 ) 
Brand Name Proge s togen Es trogen 
Or tho Novum 1 . 0 mg . SO meg . 
1/SO  norethindrone mes tranol  
Ovral O . S  mg . so meg . 
norges trel e thinyl es tradiol 
Or tho Novum 1 . 0  mg . 3S meg . 
1/3S  nore thindrone e thinyl es tradiol 
LoOvral 0 . 3  mg . 30 meg . 
norges trel e thinyl es tradiol 
Loes trin l . S  1 .  S mg . 20 meg . 
nore thindrone e thinyl es tradiol 
ace tate  
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Factors  S tudied for  Their Relevance to  Cervical Cancer 
( Ro tkin , 1 9 8 1 ) 
S oc i ocu l tur a l : 
Mar i tal : 
S exual : 
race ( increased r i s k ,  nonwhi t e )  
r e l igion ( decreased risk  among Jewish , Ami sh ,  
Mormons and Nuns ) 
economic s t a tus ( increased r i s k :  pover ty and 
depr ivation )  
educat ion ( increased risk  with less  education)  
marr iage ( increased r i s k )  
e a r l y  marr iage , mu l t iple marriage and separat ion 
( increase r i s k )  
a g e  a t  ons e t  o f  c o i tus ( increased risk  with early 
ons e t )  
number o f  s exual par tners ( increased r i s k )  
frequency o f  coi tus ( no t  related)  
prom i scu i ty ( ex treme r i s k )  
Reproduc t ive : 
n ongravid i ty/nonpari ty ( n o t  rela ted ; no risk  w i th 
cel ibacy ) 
gravidi ty/par i t y  ( no risk  demons trated) 
menses  (not related) 
con t racept ion (not resolved for oral contracept ive ) 
s ter i l i t y  ( doubt ful r i s k )  
Trauma t i c : 
abo r t i on ( n o t  related )  
i nj ury - pos tpar tum o r  from g lans ( n o t  related)  
Exogenous : 
n oncircumci s i on in coi tal  partners ( n o t  related by 
i t s e l f )  
t ransmi s s ible agen t s - sperm , HSV2 , mon i l ia , 
t r ichomonas , venereal diseas e ,  .chemica l carc inogens , 
e tc .  ( n o t  resolved , po s s ibly a l l )  
Hormones and medica t ions : ( li t t l e  inf ormation ) 
Endogenous : 
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gene tic ( no t  res olved , bu t conven t i onal  s tudies  not 
related)  
personali ty/psychosocial (not  resolved ) 
adoles cence ( direct risk  variable ) 
b lood group ( no t  related )  
Pa tho log ic : 
c e l lular morpho logy ( progress ion of  s tages ) 
s quamous metaplasia ( r � la ted to adolescenc e )  
N e w  Hypo theses : 
spec i f ic pro teins ( theoret ical , propo sed form lab) 
smoking· ( s ome evidence ,  not reso lved ) 
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Data Co l lect ion Form 
Par t One : 
C l ien t  Name 
Oral Con trac�e�p�t�l�·v�e�----------------------------
Duration o f  U s e  
- - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Par t Two : 
Age 
Race-------------------------------------------
D iagnos i s  
Par t One : 
C l ien t Name 
Oral Con tracept ive 
Dura t ion of U s e  
Par t Two : 
Age 
Race---------------------------------------------
D iagno s i s  
Par t One :  
C l ien t N arne ---,-,-------------------------------­
Oral Con t r ac ep t i ve -------------------------­
Durat ion of Use  
Par t Two : 
Age 
Race 
D i agnos i s  
Part One : 
C l ien t Name 
Or a l Contracept ive ----------------------------
Dura t ion o f  U s e  ------------------------------ -
_ _
_ _ _ _ _
_ _ _
_ _ _  
_ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Par t Two :  
Ag� -----------------------------------­
Race -�
--------------------------------------
D i agnos is  -----------------------------------
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Consen t Form f or U t i l i zat ion of Cl ien t  Medical Records 
I am a gradua te s tuden t in the Commun ity Hea l th Nurs ing 
and Fam i l y  Nurs e  Prac t i t ioner Program in the Medica l College 
of Virginia School of  Nurs ing . For my thesis , I am planning 
a re tro spec t ive s tudy concern ing the relationship be tween 
spec i f i c  oral con tracep t ives , durat ion of use and precursor 
u terine  cervical t i s sue changes . In order to obtain this  
inf orma t ion , I wou ld like to  review the medical records o f  
c l ients  s een in the Co lposcopy Clinic . N o  ident ifying data 
w i l l  be obtained f rom the record , and all informa t ion w i l l  
r emain confiden t ia l .  C l inical records meet ing s tudy cri teria 
w i l l  be repo r t ed to me by the co lposcopy nurses  and the 
f o l l owing informa t ion w i l l  be obta ined f rom the record . 
1 )  Spec i f i c  ora l con tracep t ive used by the cl ien t  
2 )  Dur a t ion o f  ora l contracept ive use  
3 )  Colposcopy d iagnosis  
4)  C l ien t age 
Thi s  s tudy has been approved by the res earch comm i t tee 
in  the M . C . V .  Schoo l  of  Nur s ing . Enclosed you wi l l  f ind a 
two page o u t l ine o f  the planned res earch . Thi s s tudy -is  to 
be conducted under the direction o f  E.  Chr i s ta S tern , Dr . P . H . , 
Schoo l o f  Nurs ing , w i th Voe lker Schneider , M . D . , M . C . V .  
Depar tmen t o f  Surgical Pathology , and Betsy Bampton , R . N . , 
COGNP , M . C . V .  Schoo l  of Nur s ing . Permi s s ion is  re9u�s t ed 
f or r eview o f  c l ien t records a t  the Colposcopy Cllnlc . 
Thank y ou . 
Consent f o r  u t i l i z a t ion o f  
Co lposcopy C l inic cl ien t  
medical records : 
Pos i t ion 
Date  
S incerely , 
Barbara J .  Fox , R . N . , B . S . N .  
Gradua te S tuden t 
M . C . V .  Schoo l  o f  Nurs ing 
E .  Chr i s ta S tern , R . N . , Dr . P . H .  
As s i s tan t  Prof e s s or 
Commun i ty Health Nurs ing 
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